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OVERLAPS: CRISIS IN THE REGULATION OF
GENETICALLY MODIFIED PLANTS AND ANIMALS
GREGORY N. MANDEL*
ABSTRACT
The regulation of genetically modified products pursuant to
statutes enacted decades prior to the advent of biotechnology has
created a regulatory system that is passive rather than proactive
about risks, has difficulty adapting to biotechnology advances, and
is highly fractured and inefficient-transgenic plants and animals
are governed by at least twelve different statutes and five different
agencies or services. The deficiencies resulting from this piecemeal
approach to regulation unnecessarily expose society and the
environment to adverse risks of biotechnology and introduce
numerous inefficiencies into the regulatory system. These risks and
inefficiencies include gaps in regulation, duplicative and inconsis-
tent regulation, unnecessary regulatory expense, agencies acting
outside their areas of expertise, and unnecessary increases in the cost
of and delay in the development and commercialization of new
biotechnology products. These deficiencies also increase the risk of
further unnecessary biotechnology scares, which may cause public
overreaction against biotechnology products, preventing the
maximization of social welfare.
With science and society poised to soar from first-generation
biotechnology (focused on crops modified for agricultural benefit), to
next-generation developments (including transgenic fish, insects,
and livestock, and pharmaceutical-producing and industrial
compound-producing plants and animals), it is necessary to
establish a comprehensive, efficient, and scientifically rigorous
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from professors David Adelman, James Gathii, and Timothy Lytton, and for helpful research
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regulatory system. This Article details how to achieve such a result
through fixing the deficiencies in, and risks created by, the current
regulatory structure. Ignoring many details, the solutions can be
summarized in two categories. First, statutory and regulatory gaps
that are identified must be closed with new legislation and regula-
tion. Second, regulation of genetically modified products must be
shifted from a haphazard model based on statutes not intended to
cover biotechnology to a system based upon agency expertise in
handling particular types of risks.
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INTRODUCTION
Biotechnology may help ameliorate some of the greatest crises
currently facing the United States and the world, including hunger
and malnutrition, environmental degradation, and widespread
disease. Genetically modifying crops through the use of biotechnol-
ogy potentially allows for greater agricultural efficiency, increased
nutritional content of food, and reduced environmental impacts.
Genetically engineering animals may create cheaper food, reduce
pressures on wild animal populations, and provide organs or
tissues for human transplant. Modifying plants and animals to
produce pharmaceuticals could provide for widespread, inexpensive
dissemination of critical pharmaceuticals and vaccines throughout
the United States and the world.
On the other hand, biotechnology could have harmful conse-
quences. Potential problems include human health impacts
resulting from the introduction of new allergens or toxins, wide-
spread environmental and ecological damage resulting from the
introduction of invasive species or loss of biodiversity, and
unforeseen injury arising from the unintentional release of
pharmaceuticals or industrial compounds into the food supply.
Most discussion concerning biotechnology takes place in a
polarized debate between biotechnology proponents who focus only
on biotechnology's advantages and generally deny its risks, and
biotechnology opponents who focus only on biotechnology's risks and
generally deny its advantages. A review of the data and information
available concerning genetically modified products demonstrates
that both camps are right, and wrong. There is now strong evidence
that genetic engineering can provide substantial health, environ-
mental, and economic benefits. There is also strong evidence that
some genetically modified products pose certain human health and
environmental risks. This Article stakes out a middle ground in the
polarized biotechnology debate: Society simultaneously should
promote the development and use of biotechnology while instituting
necessary protection against its risks.
Adequate federal regulation of biotechnology is the tool that can
best achieve both results at once. Effective and efficient regulation
is the mediator that will determine whether society reaps the
2171
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spectacular advantages of biotechnology or succumbs to its
potential dangers. Without proper regulation, society will face
unnecessary risks, the benefits of biotechnology will be slowed
severely and made more expensive, and the public will lack
confidence in biotechnology products.
Though the history of biotechnology is relatively short, it already
is filled with numerous regulatory lapses. An examination reveals
that most problems and concerns arising in this field are the result
of a deficient statutory and regulatory structure. Considering that
genetically modified products are regulated pursuant to statutes
enacted decades prior to the advent of biotechnology itself, these
deficiencies are not entirely surprising. This default system has led
to a regulatory approach that is passive rather than proactive about
risks, has difficulty adapting to biotechnology advances, and is
highly fractured-genetically modified plants and animals are
governed by at least twelve different statutes and five different
agencies or services.
The deficiencies resulting from this piecemeal approach to
regulation unnecessarily expose society and the environment to the
adverse risks of biotechnology and introduce numerous inefficien-
cies into the regulatory system. These risks and inefficiencies
include gaps in regulation and regulatory authority, duplicative and
inconsistent regulation, unnecessary regulatory expense, regulatory
agencies acting outside their areas of expertise, and unnecessary
increases in the cost of and delay in the development and commer-
cialization of new biotechnology products. These deficiencies also
result in a further risk: the failure to properly regulate biotechnol-
ogy has led to unnecessary scares (StarLink corn contamination is
the most infamous example),' which in turn cause a public overre-
action against biotechnology products, preventing society from fully
utilizing their potential benefits. Thus far, biotechnology scares
primarily are all that have occurred; deficient regulation, however,
creates the risk of more serious consequences, ones that could
retard the biotechnology industry and impair social welfare.
This Article provides solutions to the deficiencies in, and the
risks created by, the current regulatory structure. Ignoring many
details for the moment, the solutions can be summarized in two
1. See infra Part III.A.
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categories. First, numerous statutory and regulatory gaps that are
identified in this Article must be closed with new legislation and
regulation. Second, regulation of genetically modified products
must be shifted from a haphazard model based on archaic statutes
not intended to cover biotechnology to a regulatory system based
on agency expertise in handling particular types of risks. This
shift would remove from the current system numerous inefficient
instances of regulatory overlap, regulatory inconsistency, and
agencies acting outside their areas of expertise. This proposal also
would result in a regulatory structure that is both more protective
of human health and the environment and less expensive for
industry and taxpayers.
Science and society are poised to soar from first-generation
biotechnology, focused on crops genetically modified for agricul-
tural benefits, to next-generation developments including: trans-
genic fish, insects, and livestock; nutrient-enriched foods; and
pharmaceutical-producing and industrial compound-producing
plants and animals. In order to maximize the social benefit from
these advances it is necessary to establish a comprehensive,
efficient, and scientifically rigorous regulatory system to ensure
adequate protection of human health and the environment. It is
critical at this juncture to get the regulatory house in order so that
society can harvest the benefits of future biotechnological advances
without unduly suffering their risks. This Article explains and
analyzes the steps necessary to achieve this result.
Part I of this Article provides a short history of genetic modifica-
tion and an overview of the current state of biotechnology with
respect to plants and animals. Part II contains brief descriptions
and analyses of the various benefits offered and risks posed by
biotechnology. The Article turns, in Part III, to four case studies,
which highlight genetically modified product scares that have been
caused, at least in part, by regulatory deficiencies. Analyzing these
case studies yields valuable information regarding problems with
biotechnology regulation and how such problems may be cured. Part
IV provides a short primer on the current state of biotechnology
regulation by the Food and Drug Administration (FDA), the
Environmental Protection Agency (EPA), and the U.S. Department
of Agriculture (USDA). With the case studies as background, and
an understanding of genetically modified product regulation in
2173
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place, Part V identifies the regulatory gaps, overlaps, inconsisten-
cies, areas of inexperience, and other problems that exist with
respect to the regulation of biotechnology products. Part VI
discusses the causes of these regulatory deficiencies, provides
solutions for improving the current regulatory system, and
demonstrates that improved regulation is the appropriate mecha-
nism for maximizing social welfare from genetically modified
products.
I. OVERVIEW OF GENETIC MODIFICATION
In order to evaluate the regulatory system currently governing
genetically modified products, problems with the system, and how
the system should be changed, it is necessary first to become
familiar with the current status of genetically modified products in
the United States. This familiarity, in turn, requires a short history
of genetically modified products and a brief scientific introduction
to the topic.
A. The History and Science of Genetically Modified Products
Genetically modified crops, in a literal sense, have been around
for centuries, probably since the advent of agriculture. In ancient
times, farmers saved seeds from crops that produced the highest
yield, proved the hardiest, or were the most disease resistant. 2
Since at least the 1500s, farmers have bred crops in an effort to
produce more durable, productive, or marketable varieties.' Control
over genetic modification of crops took a leap forward in the late
1800s with Gregor Mendel's discoveries regarding heredity and the
inheritance of genetic traits, in particular, his finding that charac-
teristics are inherited in a logical, predictable manner.4 Since these
2. See NAT'L RESEARCH COUNCIL, ENVIRONMENTALEFFECTS OFTRANSGENIC PLANTS 37
(2002) [hereinafter NRC 2002 REPORT].
3. See John Henkel, Genetic Engineering: Fast Forwarding to Future Foods, FDA
CONSUMER, April 1995, available at httpJlwww. fda.gov/bbs/topica/CONSUMER/geneng.html
(last visited Apr. 7, 2004) ("By the 1500s, farmers were improving plants by crossing, for
example, a productive crop with a wild relative resistant to disease or pests."); see also NRC
2002 REPORT, supra note 2, at 37.
4. NAT'L RESEARCH COUNCIL, GENETICALLY MODIFIED PEST-PROTECTED PLANTS:
SCIENCE AND REGULATION 22-23 (2000) [hereinafter NRC 2000 REPORT].
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discoveries, scientists and farmers have been selectively breeding
closely related plants and animals in an effort to create hybrids
with superior characteristics. Today, there are virtually no food
products in supermarkets that have not been improved in some
manner by selective breeding.5 Genetic modification through the
breeding of plants and animals (which will be referred to as
"conventional genetic modification"), however, is labor intensive
(only one out of thousands of hybrids becomes a useful variety), can
only be done among closely related species, takes a long time to
produce desired results (usually a decade), and is often imprecise.6
Scientists now are able to take genetic material responsible for
a particular trait in one living species (whether plant, animal,
insect, bacterium, or virus), and insert it into another species.
Because the DNA building blocks for all living things are similar,
desirable genes from any living organism can be inserted into any
other living organism. This allows for modification of organisms at
the cellular level, as opposed to conventional modification via
breeding of the entire organism.' If the genetic insertion is success-
ful, the new genetic material in the host organism does what most
genes do-it directs the production of specific proteins.8 This
method of modification uses recombinant DNA (rDNA) techniques,
and is referred to as rDNA genetic modification. The modified
rDNA organisms are commonly referred to as "genetically modi-
fied," "genetically engineered," "bioengineered," or "transgenic."9
5. ROYAL SOC'Y OF CAN., ELEMENTS OF PRECAUTION: RECOMMENDATIONS FOR THE
REGULATION OF FOOD BIOTECHNOLOGY IN CANADA 16 (2001). Wild blueberries are one of the
few remaining unmodified plant products. Id. Examples of foods that have undergone
particularly dramatic changes through conventional genetic modification include edible ears
of corn (as opposed to corn with hard kernels that could not be eaten until ground into flour)
and the kiwi (a fruit developed from a hard little berry). Henkel, supra note 3.
6. NRC 2002 REPORT, supra note 2, at 43; NRC 2000 REPORT, supra note 4, at 23.
7. MARGARET MELLON, BIOTECHNOLOGY AND THE ENVIRONMENT: A PRIMER ON THE
ENVIRONMENTAL IMPLICATIONS OF GENETIC ENGINEERING 20 (1988).
8. BRUCE ALBERTS ETAL., MOLECULAR BIOLOGYOFTHE CELL 200 (4th ed. 2002); Thomas
0. McGarity, Seeds of Distrust: Federal Regulation of Genetically Modified Foods, 35 U.
MICH. J.L. REFORM 403, 407 (2002). The two most common methods of genetic engineering
are splicing the gene to be transferred to a virus and infecting the host organism with the
virus, and coating tiny metal particles with the gene to be transferred and then fring the
particles into the host cells. See ROYAL SOC'Y OF CAN., supra note 5, at 16-17.
9. Except as otherwise stated, the terms "genetically modified," "genetically engineered,"
"bioengineered," and "transgenic" are used synonymously in this Article, each referring to
the direct transfer or modification of genetic material using rDNA techniques.
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rDNA genetic engineering offers many advantages over conven-
tional breeding techniques. First, the organism being modified does
not have to be sexually compatible with the organism from which
the genetic material comes--one can take genes from bacteria and
implant them into plants or animals, and vice versa. 10 Second, new
varieties can be produced much faster through rDNA methods
than through conventional breeding techniques.'1 Third, specific
knowledge of the trait caused by the particular DNA being trans-
ferred can reduce variability in the offspring organisms.
12
B. Current Status of Genetically Modified Products
Many people are surprised to learn that genetically modified food
is already pervasive in the United States. Almost everyone reading
this Article already has eaten genetically modified food, and likely
has done so today.'3
The first genetically modified commercial food item, the Flavr
Savr tomato (a slow-ripening tomato), was introduced in 1994.'"
Since that time, genetically modified foods have become wide-
spread, as over fifty types of transgenic plants have been commer-
cialized in the United States.'5 These plants include delayed-
10. NRC 2002 REPORT, supra note 2, at 43.
11. NRC 2000 REPORT, supra note 4, at 23.
12. Id. at 23-24. Genetic engineering, however, also can be imprecise. MARTIN TEITEL &
KIMBERLY A. WILSON, GENETICALLY ENGINEERED FOOD: CHANGING THE NATURE OF NATURE
10 (2001).
13. See infra notes 19-20 and accompanying text. Only one in four people are aware that
they have eaten genetically modified food. Memorandum from The Mellon Group, Inc. and
Public Opinion Strategies, Inc., to The Pew Initiative on Food and Biotechnology 2 (Sept. 15,
2003) (on file with author).
14. TEITEL&WILSON, supra note 12, at 21. The Flavr Savr was not a commercial success.
Id. at 22. The first genetically engineered plant was created in 1983; genetically modified
plants were first grown in the field in 1987. Id. at 18.
15. See CTR. FOR FOOD SAFETY & APPLIED NUTRITION, OFFICE OF FOOD ADDITIVE SAFETY,
U.S. FOOD & DRUG ADMIN., LIST OF COMPLETED CONSULTATIONS ON BIOENGINEERED FOODS
(2002) [hereinafter BIOENGINEERED FOODS LIST], available at http://www.cfsan.
fda.gov/-Ird/biocon.html (last visited Apr. 7, 2004) (listing fifty-five submissions completed
between 1994 and 2002); see also INFO. SYS. FOR BIOTECHNOLOGY, TABLES FOR FIELD TEST
RELEASES IN THE U.S. (last updated Mar. 26, 2004) [hereinafter TABLES FOR FIELD TEST
RELEASES], at http://www.isb.vt.edu/cfdocs/isbtables2.cfmtvar=4 (last visited Apr. 7, 2004)
(reporting that sixty genetically modified plants have been deregulated). The Animal and
Plant Health Inspection Service (APHIS) section of the U.S. Department of Agriculture is
responsible for issuing permits and approving or denying the application for the release of
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ripening crops, pest-resistant crops, herbicide-tolerant crops, virus-
resistant crops, bacteria-resistant crops, fungus-resistant crops, and
nematode-resistant crops, among others.
16
Genetically engineered plants were grown on over one hundred
million acres of American farmland in 2003, up from a mere six
million acres in 1996.17 In 2003, 81% of soybeans, 40% of corn, and
73% of cotton grown in the United States were grown from geneti-
cally modified seeds; over half of the canola and papaya were
genetically engineered as well."8 The Grocery Manufacturers of
America estimates that 70% of food on grocery store shelves
contains ingredients from genetically modified crops, 9 in everything
from cereals and crackers, to juice and soda, to salad dressing and
sauces.
20
genetically modified organisms. See INFO. SYS. FOR BIOTECHNOLOGY, BACKGROUND ON THE
ENVIRONMENTAL RELEASES DATABASE, at http://www.isb.vt.edu/biomon/explain.cfm (last
visited Apr. 7, 2004).
16. See, e.g., INFO. SYS. FOR BIOTECHNOLOGY, CHARTS FOR FIELD TEST RELEASE IN THE
U.S. (last updated Mar. 26,2004), at http://www.isb.vt.edu/cfdocs/biochartsl.cfm (lastvisited
Apr. 7, 2004).
17. NAT'L AGRIC. STATISTICS SERV., U.S. DEPT OF ARGIC., ACREAGE 24-25 (June 2003),
available at http://usda.mannlib.cornell.edu/reportsnassr/field/pcp-bba/acrg603.pdf (last
visited Apr. 7,2004); TEITEL & WILSON, supra note 12, at 18. Growth of genetically modified
crops in the United States dominates the worldwide industry, accounting for two-thirds of
the global transgenic crop. See PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, FACTSHEET:
GENETICALLY MODIFIED CROPS IN THE UNITED STATES [hereinafter PEW INITIATIVE
FACTSHEET], available at http://pewagbiotech.org/resources/factsheets/display.
php3?FactsheetlD=2 (Aug. 2003). The United States, Argentina, Canada, and China
combined account for 99% of genetically modified crop production. Id.
18. PEW INITIATIVE FACTSHEET, supra note 17.
19. David Barboza, Modified Foods Put Companies in a Quandary: Science Is Called
Sound but Public Is Not Sure, N.Y. TIMES, June 4, 2000, at Al; see also Rick Weiss, Biotech
Food Raises a Crop of Questions, WASH. POST, Aug. 15, 1999, at Al ("[Nlearly everything
made with soy, corn, or cotton in this country ends up containing at least some gene-altered
ingredients.").
20. See NATURAL LIFE, SHOP TO AVOID GENETICALLY ENGINEERED FOOD, at
http://www.life.ca/nl/60/avoidbiotech.html (last visited Mar. 16,2004). Examples of common
food items containing genetically modified components include Fritos corn chips, McDonald's
french fries, Coca-Cola, and Nestle's chocolates. Id. Close to fifty different types of crops have
been genetically modified (not all have been commercialized, some are still under
development), including alfalfa, apple, barley, beet, broccoli, carrot, cassava, citrus, coffee,
corn, cotton, cranberry, cucumber, eggplant, grape, grapefruit, lettuce, melon, oat, onion,
papaya, pea, peanut, pear, pepper, peppermint, persimmon, pineapple, plum, potato,
radicchio, rapeseed (canola), raspberry, rice, soybean, squash, stone fruit, strawberry,
sugarbeet, sugarcane, sunflower, sweet potato, tomato, walnut, watermelon, and wheat.
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Genetically modified crops are likely to become more varied and
pervasive. The first generation of crops was altered primarily to
provide agricultural benefits, such as pest resistance and herbi-
cide tolerance. Next-generation crops will be manipulated to
create more nutritious foods, and to produce plants that grow
nonfood products, such as pharmaceuticals, vaccines, vitamins, and
industrial compounds.2 Numerous companies are working on
producing pharmaceuticals that grow in plants. Once grown, the
pharmaceuticals can be extracted from the plant, or in some
instances people may be able to eat the genetically engineered plant
to obtain the benefit.22 Relatedly, plants may be used to grow
industrial compounds for uses such as detergent manufacturing,
paper production, and mineral recovery.2"
Various species of trees are being genetically engineered to grow
faster, produce wood that is easier to process, or resist certain
diseases and other problems.24 Many laboratories are working on
varieties of genetically modified fish, such as transgenic salmon,
carp, catfish, and trout, in an effort to increase rates of growth and
reproduction, improve disease resistance, enhance cold tolerance,
or provide other benefits.25 Proposals for the commercialization of
these fish are currently under review.26
IMPROVING PEST MANAGEMENT IN U.S. AGRICULTURE 4-8, 16 (2002); MICHAEL R. TAYLOR &
JODY S. TICK, POST-MARKET OVERSIGHT OF BIOTECH FOODS: Is THE SYSTEM PREPARED? 20
n.19 (2003).
21. See Proposed Federal Actions To Update Field Test Requirements for Biotechnology
Derived Plants and To Establish Early Food Safety Assessments for New Proteins Produced
by Such Plants, 67 Fed. Reg. 50,578 (Aug. 2, 2002) (to be codified at 7 C.F.R. pt. 340)
[hereinafter Proposed Field Test Requirements]; Premarket Notice Concerning
Bioengineered Foods, 66 Fed. Reg. 4706, 4714 (proposed Jan. 18, 2001) (to be codified at 21
C.F.R. pts. 192, 592).
22. Andrew Pollack, New Ventures Aim To Put Farms in Vanguard of Drug Production,
N.Y. TIMES, May 14, 2000, at Al.
23. Field Testing of Plants Engineered To Produce Pharmaceutical and Industrial
Compounds, 68 Fed. Reg. 11,337, 11,338 (proposed Mar. 10, 2003) (to be codified at 7 C.F.R.
pt. 340) [hereinafter Field Testing of Pharmaceutical Plants].
24. LUKE ANDERSON, GENETIC ENGINEERING, FOOD, AND OUR ENVIRONMENT 41-42 (2000);
ROYAL SOC'Y OF CAN., supra note 5, at 28.
25. See, e.g, PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, FUTURE FISH: ISSUES IN
SCIENCE AND REGULATION OF TRANSGENIC FISH 5-7 (2003) [hereinafter FUTURE FISH]. Other
traits scientists are investigating include modification to allow marine fish to be raised in
fresh water, improving tolerance to various environmental conditions, and enhancing
nutritional qualities. See id. at 5; ROYAL SOCY OF CAN., supra note 5, at 27.
26. See, e.g., FUTURE FISH, supra note 25, at 5-6. On the novelty front, an aquarium fish
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Transgenic cattle, sheep, pigs, chickens, goats, rabbits, rodents,
shellfish, and insects also are being developed.2 ' Goals here include
increasing growth rates, reducing fat levels, and improving disease
tolerance, among others.28 Experimentation is under way to
genetically engineer animals to produce human biologics and other
products, including organs and tissues for human transplant.29
Animals could be modified to produce human proteins in their milk,
which could then be extracted and purified for therapeutic use in
humans.3 0
In sum, genetically modified crops are already widely commer-
cialized, and the commercialization of many next-generation
biotechnology products is just around the corner. Further, develop-
ments in rDNA technology and genomics, including the genetic
sequencing of plants, are expected to lead to the accelerated
development of even more new biotechnology products, both in
number and diversity.3 '
II. BENEFITS AND RISKS OF GENETICALLY MODIFIED PLANTS AND
ANIMALS
No decision regarding how to use and regulate genetically
modified products can be made without an understanding of their
potential benefits and possible risks. This Part provides an
overview of current scientific knowledge regarding the benefits and
risks of genetically modified products.32
genetically modified to glow in the dark recently was commercialized. Andrew Pollack, So,
the Fish Glow, But Will They Sell?, N.Y. TIMES, Jan. 25, 2004, at C5.
27. See NATL RESEARCH COUNCIL, ANIMAL BIOTECHNOLOGY: SCIENCE-BASED CONCERNS
76-83 (2002) [hereinafter ANIMAL BIOTECHNOLOGY].
28. ANDERSON, supra note 24, at 75.
29. ANIMAL BIOTECHNOLOGY, supra note 27, at 16; see also id. at 51-54.
30. See, e.g., COUNCIL ONENVTL. QUALITY& OFFICE OF SCI. & TECH. POLICY, CASE STUDY
No. IV: FARM ANIMAL (GOAT) THAT PRODUCES HUMAN DRUGS 1 (2001) [hereinafter CASE
STUDY No. IV: FARM ANIMAL THAT PRODUCES HUMAN DRUGS], available at
http://www.ostp.gov/html/ceq-ostp-study5.pdf (last visited Apr. 7, 2004). Other biologic
products, such as therapeutic, blood, and vaccine products may be developed in this manner
as well. Id.
31. See NAT'L RESEARCH COUNCIL, EXPLORING HORIZONS FOR DOMESTIC ANIMAL
GENOMICS 1-4 (2002); see also Proposed Field Test Requirements, supra note 21,67 Fed. Reg.
at 50,578; Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4709
(proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592).
32. Determining the potential benefits and risks of genetically modified products is a
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A. Potential Benefits of Genetic Engineering
The commercialization of genetically modified crops potentially
has many great societal advantages, ranging from increased
agricultural efficiency, to nutritional improvement, to environmen-
tal protection. Anticipated future developments in biotechnology
promise even more benefits. Each category of benefits is discussed
below.
1. Agricultural Benefits
The growth of genetically modified crops may allow for the
production of greater quantities of food more easily and at cheaper
cost than conventional plants. Approximately $14 billion worth of
crops are lost each year in the United States due to plant pests.33
Part of this crop loss can be reduced through the use of crops
genetically modified to include an internal pesticide (so-called "pest-
daunting process because of the scientific uncertainty in this area and the highly polarized
debate concerning these products. As discussed in the Introduction, the literature and
scientific reports coming from biotechnology proponents describe far more benefits and fewer
risks than those from biotechnology opponents, which describe many risks and few or no
benefits. Each side routinely accuses the other of bias in their scientific results; both sides
have numerous scientists with Ph.Ds in relevant fields in their camps. The issues of which
information to rely on and of bias in scientific information are therefore critical to this
analysis.
The description of the benefits and risks of genetically modified plants and animals that
follows, therefore, necessarily contains much cautionary language, discussing, for instance,
.possible" benefits and "potential" risks. The benefits and risks described here, to the
greatest extent possible, are those on which there is a significant degree of scientific
consensus and which are published in independent, peer-reviewed publications. Where there
is not this level of agreement on a benefit or a risk, the text and footnotes note the
disagreement.
Somewhat unexpectedly, and perhaps somewhat reassuringly, reliance on independent,
peer-reviewed publications leads to a relatively uniform reporting and analysis of the
potential benefits and risks of genetically modified plants and animals, as discussed in Part
III, infra.
33. See David Pinentel, Economic and Environmental Impacts of Invasive Species and
Their Management, 21 PESTICIDES AND YOU 10, 10 (2001), available at http://www.
beyondpesticides.org/infoservices/pesticidesandyou (last visited Apr. 7,2004) ("It is estimated
that introduced insect pests cause nearly $14 billion in U.S. crop losses each year."); cf NRC
2000 Report, supra note 4, at 19 ("An estimated $7 billion in crop losses per year in the
United States are caused by nematodes ... and even greater losses are caused by arthropod
pests.") (citation omitted).
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protected" plants), improving both the yield and the quality of the
crop.3 4 Certain pest-protected corn, for instance, may increase yields
from 1.8% to 8.1%.31 Use of pest-protected plants also may lower
production costs because growers will not have to pay for the
pesticides themselves, or for their transportation, application, and
disposal.3 6
Crops also are being genetically engineered to be tolerant of
certain herbicides. Growers then can use specific herbicides on their
crops without injuring the herbicide-tolerant crops themselves, thus
increasing yields. 7 Such uses also may reduce costs. One study
found that use of a particular herbicide-tolerant soybean resulted
in a total production cost reduction of 6%."8 Other crops have been
modified to be disease-resistant and drought-resistant, with obvious
benefits for agricultural yield and quality. 9 In addition, crops may
be modified to enable them to grow in temperatures, soils, weather,
and climates that would normally prohibit cultivation.40
Data from the 2001 growing season indicate that genetically
modified crops in the United States increased yields by four billion
pounds, and at the same time saved growers $1.2 billion by
lowering production costs, resulting in total net savings of $1.5
billion. 1 Analyses of transgenic crops under development indicate
that such varieties could increase crop yields by an additional ten
34. NRC 2000 REPORT, supra note 4, at 46.
35. GERALD C. NELSON ET AL., THE ECONOMICS AND POLITICS OF GENETICALLY MODIFIED
ORGANISMS IN AGRICULTURE: IMPLICATIONS FOR WTO 2000, at 27 (1999).
36. See COUNCIL ON ENVTL. QUALITY & OFFICE OF SCI. & TECH. POLICY, CASE STUDY No.
II: BT-MAIZE 22-23 (2001) [hereinafter CASE STUDY No. II: BT-MAIZE], available at
http://www.ostp.gov/ htmllceqostp-study3.pdf (last visited Apr. 7, 2004).
37. McGarity, supra note 8, at 412.
38. NELSON ETAL., supra note 35, at 18.
39. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4727
(proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592).
40. McGarity, supra note 8, at 413.
41. GIANESSI ET AL., supra note 20, at 40, 55. A separate, earlier National Research
Council study found that increased yields were reported by many, but not all, growers. See
NRC 2000REPORT, supra note 4, at 33 (describing a reduced need for chemical pesticides and
increased yields among many growers using transgenic pest-protected crops). Another report
found that the first generation of transgenic corn and soybeans, if adopted globally, "would
increase production by only an estimated [two] percent or less." HENRYA. WALLACE CTR. FOR
AGRIC. & ENVTL. POLICY, WINROCK INT'L, TRANSGENIC CROPS: AN ENvIRONMENTAL
ASSESSMENT 8 (2000), available at http://www.winrock.org/general/Publications/transgenic.
pdf (last visited Apr. 7, 2004).
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billion pounds per year and result in net economic savings of $1
billion per year.42 All told, the net value of the existing genetically
modified crops and those in development was estimated to be $2.5
billion, based on the increased value of the crops plus reductions in
grower costs.
43
Increased agricultural yields and lower grower costs should
make food less expensive for consumers, in turn helping to reduce
national and international hunger problems and save lives. 4"
Though the 5% reductions in cost or increases in yield mentioned
earlier may not sound significant, estimates are that even a limited
worldwide adoption of genetically modified products that increase
productivity by 5% would result in economic welfare gains of tens
of billions of dollars.'
With the world's population growing exponentially, estimates
show that agricultural production will need to be doubled over the
next fifty years to keep pace with population growth. 4' Genetically
engineered crops offer a way to accomplish a portion of this task.
The National Academy of Sciences, in concert with six foreign
academies of science, has urged the increased use and development
of biotechnology crops to solve problems of hunger and poverty in
developing nations."'
42. GIANESSI ETAL., supra note 20, at 55.
43. Id.
44. Some critics contend that a greater supply of inexpensive food would do little to ease
worldwide hunger, as the problem is one of inadequate resources for the delivery of food, not
inadequate supply. See, e.g., TEITEL & WILSON, supra note 12, at 116-17; Ellen Messer, Food
Systems and Dietary Perspective: Are Genetically Modified Organisms the Best Way To
Ensure Nutritionally Adequate Food?, 9 IND. J. GLOBAL LEGAL STUD. 65, 68 (2001) (arguing
that the food crisis results from insufficient markets, not insufficient production). Many
experts dispute the absolute nature of this claim, noting that though delivery problems may
be important, additional supply will certainly aid in the hunger crisis. See, e.g., id. at 69-70.
Similarly, creating crops that can grow in a wider variety of environments will make food
more available in many regions of the world.
45. KYM ANDERSON ET AL., ESTIMATING THE ECONOMIC EFFECTS OF GMOS: THE
IMPORTANCE OF POLICY CHOICES AND PREFERENCES 15 (CIES, Adelaide Univ., Policy
Discussion Paper No. 35, 2000), available at http://www.adelaide.edu.au/cies0035.pdf (last
visited Apr. 7, 2004).
46. Lakshman D. Guruswamy, Sustainable Agriculture: Do GMOs Imperil Biosafety?, 9
IND. J. GLOBAL LEGAL STUD. 461,466 (2002).
47. Carol Kaesuk Yoon, Call for Use of New Crops, N.Y. TIMES, July 11, 2000, at C4. This
report was issued in conjunction with the Royal Society of London, the Brazilian Academy
of Sciences, the Chinese Academy of Sciences, the Indian National Academy of Sciences, the
Mexican Academy of Sciences, and the Third World Academy of Sciences. See ROYAL Soc'v
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2. Human Health and Consumer Benefits
In addition to making food less expensive, genetic modification of
crops also may allow for the growth of more nutritious food and the
consumption of food that tastes better. More nutritious foods could
include plant products that are modified to contain higher-than-
natural levels of vitamins, minerals, desirable dietary fats, and
antioxidants.4 ' In one commonly cited example, Monsanto Corpora-
tion has agreed to make available, free or at cost, genetically
modified rice (called "golden rice") that is rich in beta carotene, a
precursor to vitamin A."9 This may aid in reducing health problems
associated with vitamin A deficiencies, which contribute to illness
and death for approximately ten million people globally each year.50
Pest-resistant crops and crops that stay fresh longer will yield
fruits and vegetables that are better looking and have less
damage.5' In addition, the use of pest-resistant crops will result in
marketed fruits and vegetables containing less spray-pesticide
OF LONDON ETAL., TRANSGENIC PLANTS AND WORLD AGRICULTURE (July 2000), available at
http://books.nap.edu/html/transgenic/pdf/transgenic.pdf(last visited Apr. 7, 2004). The report
called for regulatory systems to be established to monitor health risks from genetically
modified plants and for research into environmental and food-safety risks. Id. at 2. Scientists
critical of the report contend that the scientists supporting the report are those who have
made their career in the area of genetically modified food, and may be influenced by a
personal interest in funding. Yoon, supra; see also Christopher Marquis, Monsanto Plans To
Offer Rights to its Altered-Rice Technology, N.Y. TIMES, Aug. 4, 2000, at All.
48. NRC 2002 REPORT, supra note 2, at 222; TAYLOR & TICK, supra note 20, at 8; TEITEL
& WILSON, supra note 12, at 131-32.
49. COUNCIL ON ENVTL. QUALITY & OFFICE OF Sci. & TECH. POLICY, CEQ AND OSTP
ASSESSMENT: CASE STUDIES OF ENVIRONMENTAL REGULATIONS FOR BIOTECHNOLOGY 2 (2001)
[hereinafter CEQ AND OSTP ASSESSMENT], available at http:/www.ostp.gov/html/ceq-ostp-
studyl.pdf (last visited Apr. 7, 2004); see also Marquis, supra note 47, at All; Messer, supra
note 44, at 67. Golden rice represents a particular scientific advance. Most genetically
modified products have involved the insertion of a single gene or multiple single genes.
Golden rice introduces four stacked genes, ushering in the generation of more complex
multigene transfers. Id. at 77.
50. NRC 2002 REPORT, supra note 2, at 226-27; see also CEQ AND OSTP ASSESSMENT,
supra note 49, at 2. There is scientific controversy regarding whether the additional beta
carotene will be successfully transformed by malnourished people into vitamin A. NRC 2002
REPORT, supra note 2, at 226-27; TEITEL & WILSON, supra note 12, at 134.
51. See NRC 2002 REPORT, supra note 2, at 222 (describing how transgenic plants may
have an improved shelf life); McGarity, supra note 8, at 415 (describing how biotechnology
could lead to better looking crops that retain freshness for longer periods of time).
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residue.52 Though not commercially successful yet, scientists also
are trying to engineer crops to stay fresh and firm for longer periods
of time and to improve their flavor.53
Genetic engineering may improve food safety along other lines.
It may be used to reduce the allergenic risks associated with certain
foods,54 and may allow scientists to remove the genes that cause
some toxins to form in certain plants.55
3. Environmental and Ecological Benefits
A potentially great advantage of transgenic crops is the many
indirect benefits they may provide for the environment. As over half
the land in the United States is used for crop and animal produc-
tion,5" environmental benefits from bioengineering will be wide-
spread.
Many genetically modified crops have been modified to include a
natural pesticide. Growth of these pest-protected plants should
reduce or eliminate the need for pesticide spraying, reducing the
amount of harmful pesticide residue left in the environment.57 In
addition, genetically modified pest-protected plants have specific
insect targets, whereas traditional pesticides are broad-spectrum
52. "In the United States, approximately thirty-five percent ofall foods in supermarkets
have detectable pesticide residues, and at least one to three percent of all foods have residues
above the Food and Drug Administration's acceptable tolerance level." David Pimentel,
Overview of the Use of Genetically Modified Organisms and Pesticides in Agriculture, 9 IND.
J. GLOBAL LEGAL STUD. 51, 58 (2001).
53. TAYLOR & TICK, supra note 20, at 8; McGarity, supra note 8, at 414.
54. NRC 2000 REPORT, supra note 4, at 36; see also Andrew Pollack, Gene Jugglers Take
to Fields for Food Allergy Vanishing Act, N.Y. TIMES, Oct. 15, 2002, at F2. Projects are
underway to reduce the allergenicity of soybeans, wheat, rice, peanuts, ryegrass, and castor
plants. Id.
55. See NRC 2002 Report, supra note 2, at 44 (describing how tumor-producing genes are
removed from the vectors used to genetically engineer crop plants).
56. NRC 2002 REPORT, supra note 2, at 22; see also ROYAL SOCY OF CAN., supra note 5,
at 130 (explaining that 70% of U.K. land and 11% of Canadian land are under some form of
agriculture).
57. CASE STUDY No. II: BT-MAIZE, supra note 36, at 22-23; see also NRC 2000 REPORT,
supra note 4, at 6, 63. One early study found that 3.5% less active pesticide ingredients were
used in 1998 compared with 1997, a decrease which corresponded with increased adoption
of transgenic crops. L. L. Wolfenbarger & P. R. Phifer, The Ecological Risks and Benefits of
Genetically Engineered Plants, 290 SCIENCE 2088, 2090-91 (2000). About 1% of the decline
was attributed to the use of the transgenic crops, as opposed to other fluctuating factors such
as pest problems, weather, and cropping patterns. Id.
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chemical insecticides that kill many nontarget insects indiscrimi-
nately.58
To cite one example, many crops have been engineered to contain
genes from the bacterium Bacillus thuringiensis (Bt). Bt naturally
produces several proteins that are toxic to certain insects when
ingested. Mixtures of various subspecies of Bt, created in order to
affect as many insect species as possible, have been used conven-
tionally to spray crops for over fifty years. When used as a spray,
however, applications have to be made frequently, with concomitant
residue left in the environment. In genetically modified Bt crops,
production of the insecticide occurs continuously, eliminating the
need for spraying.59
Data appear to show that benefits are accruing. Information from
the 2001 growing season indicates that the use of genetically
modified crops reduced pesticide use by forty-six million pounds. 0
The introduction of additional transgenic crops under development
is estimated potentially to cut pesticide use by an additional 117
million pounds.6' Many of the transgenic pest-protected plants were
found to be effective at controlling pests, and a reduced need for
chemical pesticide application and increased yields were reported
by many, though not all, genetically modified crop growers.62
Herbicide-tolerant crops similarly may have environmental
benefits. Use of these crops should allow farmers to stop using or
reduce their use of preemergent herbicides and rely instead on
postemergent ones. Preemergent herbicides are incorporated into
the soil, requiring more tillage, which in turn leads to greater
soil erosion, water loss, and reduction in soil organic matter. 3 All
of these detrimental effects would be reduced by a shift to
postemergent herbicides.
Lastly, the greatest threat to biodiversity today is likely habitat
loss. 6 4 Bioengineering plants may reduce habitat loss through
58. NRC 2000 REPORT, supra note 4, at 37.
59. Id. at 27-28.
60. GJANESSI ETAL., supra note 20, at 55.
61. Id.
62. NRC 2000 REPORT, supra note 4, at 33. One report found that insecticide sprays used
on cotton in 1998 were reduced from an average of 8.3 applications for conventional cotton
to an average of 6.0 applications for Bt cotton. Id. at 33-34, 114.
63. Wolfenbarger & Phifer, supra note 57, at 2091.
64. John S. Applegate, The Prometheus Principle: Using the Precautionary Principle To
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increased crop yields. As noted above, it is estimated that agricul-
tural production will need to double over the next fifty years.6"
There are only two ways to achieve greater agricultural production:
increasing yield efficiency or devoting more land to agriculture. 6
Doubling the amount of land currently devoted to agriculture would
have devastating environmental and ecological effects-recall that
one-half of the United States' land is already used for plant and
animal production.67 Achieving greater crop yield from existing
agricultural lands, on the other hand, would decrease the pressure
to develop currently undeveloped natural habitats, offering many
ecological and environmental benefits.68
4. Next- Generation Biotechnology Benefits
The potential benefits of future biotechnology advances are as
varied as the products themselves. These advantages include
widespread health, environmental, and economic benefits.
Numerous advances are occurring with transgenic plants.
Researchers are genetically engineering plants to remove toxic
heavy metals from contaminated waters and soils.69 Scientists are
genetically engineering trees to make them resistant to insects
and herbicides, and to increase their rate of growth.7 ° Other
modifications may make the use of trees in the paper production
process more efficient and reduce environmental pollution from
paper production.71
Scientists are well advanced in genetically modifying plants to
produce drugs, including antibodies, vaccines, pharmaceuticals, and
human proteins.72 Such an achievement will make drug production
Harmonize the Regulation of Genetically Modified Organisms, 9 IND. J. GLOBALLEGAL STUD.
207, 225 (2001); Wolfenbarger & Phifer, supra note 57, at 2091.
65. See supra text accompanying note 46.
66. Guruswamy, supra note 46, at 466.
67. See supra text accompanying note 56.
68. See Applegate, supra note 64, at 224-25; see also Wolfenbarger & Phifer, supra note
57.
69. NRC 2002 REPORT, supra note 2, at 229; see also Wolfenbarger & Phifer, supra note
57, at 2091 (describing how the use of transgenic crops may reduce the need to use toxic
chemicals to protect crops).
70. NRC 2002 REPORT, supra note 2, at 222.
71. Id. at 223.
72. TEITEL & WILSON, supra note 12, at 130.
2186 [Vol. 45:2167
20041 GENETICALLY MODIFIED PLANTS AND ANIMALS
cheaper and could make drugs, particularly vaccines, far more
available in developing countries.7 An example of one such attempt
is the modification of tobacco plants to produce a drug that will
stimulate the production of platelets in bone marrow. This drug
could be extracted from tobacco plants, purified, and used in
treating human cancer patients who have received chemotherapy. 4
Other plant-produced pharmaceuticals currently in, or soon to be
in, clinical trials include those to treat E.coli, non-Hodgkins
lymphoma, cystic fibrosis, and herpes. 5 Though plant-produced
pharmaceuticals are not yet commercialized in the United States,
in Canada an anticoagulant agent is now being produced commer-
cially in transgenic plants.76 With the cost of health care ranking as
one of the United States' greatest concerns, the inexpensive
production of pharmaceuticals would be greatly beneficial.
Plants also are being genetically modified to grow industrial
compounds, such as enzymes and other proteins, oils, waxes, and
plastics." Such advances not only may produce economic benefits,
but also may provide substantial environmental benefits, for
instance, by replacing conventional plastics with biodegradable
polymers.78 Plants genetically engineered to store more carbon
could have a role in combating global warming.79
Though genetically modified animals and the products they
produce have not yet been commercialized, many developments
are underway and offer myriad benefits.80 Bioengineered fish could
73. See Pollack, supra note 22, at A26; see also TEITEL & WILSON, supra note 12, at 130-
31. An experiment involving a potato genetically engineered to provide an oral vaccine was
successful. TEITEL & WILSON, supra note 12, at 134-35; COUNCIL ON ENVTL. QUALITY &
OFFICE OF SCI. & TECH. POLICY, CASE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN 49
(2001) [hereinafter CASE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN], available at
http://www.ostp.gov/html/ceq..ostf study4.pdf (last visited Apr. 7, 2004).
74. CASE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN, supra note 73, at 47.
75. BIOTECHNOLOGY INDUS. ORG., PLANT-MADE PHARMACEUTICALS: FREQUENTLY ASKED
QUESTIONS, at http://www.bio.org/pmp/factsheet2.asp (last visited Apr. 7, 2004).
76. TAYLOR & TICK, supra note 20, at 20.
77. Id. at 21.
78. Id.
79. See Can Ag Biotech Help Solve Energy and Global Warming Problems?, AGBIOTECH
BUZZ, vol. 3, no. 4, July 22, 2003, available at http://pewagbiotech.orgtbuzz/display.
php3?StoryID= 107 (last visited Mar. 16, 2004) (arguing that genomics could help to advance
the creation of carbon-neutral fuels such as ethanol).
80. The process of genetically modifying animals is significantly more complicated than
genetic modification ofplants, though the goal is the same: inserting foreign DNA into a host
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decrease harvest pressure on wild fisheries, many of which
currently are endangered or threatened."s One version of genetically
modified salmon at an advanced stage of development is modified
to use feed more efficiently and to grow rapidly. These traits will
reduce the resources needed to grow salmon and reduce the amount
of waste generated, consequently lowering the market cost of the
salmon and reducing the harm to the environment per salmon
raised.s2
Farm animals such as poultry, swine, goats, cattle, and other
livestock are being genetically modified to improve growth rate,
feed efficiency, and disease resistance.8 " There may be other
benefits as well. For instance, genetic engineering may allow for the
removal of a gene associated with mad cow disease from cattle.84
Genetic modification of livestock also may improve the nutritional
composition for the animals' use as human food and reduce
pressure on the development of agricultural land. 5 Food products
produced by transgenic animals could include milk lacking the most
common allergenic protein, eggs lower in cholesterol, and meat with
greater vitamin content or modified fat content. 6
Animals including poultry, swine, rabbit, goats, sheep, and cattle
are being modified to produce pharmaceuticals or other products
and to serve as potential sources for replacement organs or tissues
for humans.8 7 The production of human proteins in the milk of
transgenic animals could provide an efficient method for producing
such proteins and reduce the cost of pharmaceutical manufactur-
organism. For a brief discussion of the methods used to genetically modify animals, see
ANIMAL BIOTECHNOLOGY, supra note 27, at 36-49.
81. COUNCIL ON ENVTL. QUALITY & OFFICE OF SCI. & TECH. POLICY, CASE STUDY No. I:
GROWTH-ENHANCED SALMON 9 (2001) [hereinafter CASE STUDY No. I: GROWTH-ENHANCED
SALMON], available at http:/www.ostp.gov/html/ceq-ostp- study2.pdf (last visited Apr. 7,
2004); see also Carl Safma, The World's Imperiled Fish, SCI. AM., Nov. 1995, at 46, 48-50
(describing the collapse of many fisheries worldwide as a result of industrial overfishing).
82. ANIMAL BIOTECHNOLOGY, supra note 27, at 89-90; FUTURE FISH, supra note 25, at 10,
15-16; CASE STUDY NO. I: GROWTH-ENHANCED SALMON, supra note 81, at 9.
83. ROYAL SOC'Y OF CAN., supra note 5, at 90; see also ANIMAL BIOTECHNOLOGY, supra
note 27, at 34 (describing how genetically engineered animals can be produced to have useful
novel properties for increased protein, for biomedical purposes, and for human consumption).
84. ANIMAL BIOTECHNOLOGY, supra note 27, at 37.
85. Id. at 16; ROYAL SOC'Y OF CAN., supra note 5, at 90.
86. ANIMAL BIOTECHNOLOGY, supra note 27, at 67.
87. Id. at 16, 51; see also CASE STUDY No. IV: FARM ANIMAL THAT PRODUCES HUMAN
DRUGS, supra note 30, at 1.
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ing.88 Such production also may provide environmental benefits by
reducing the amount of energy and other manufacturing inputs
consumed during the production of protein.89 The growth of organs
in animals for human transplant could have substantial human
health benefits due to the enormous shortage of human organs
currently available for transplant. 90
Transgenic insects are being developed as well. Insects domesti-
cated for farming, such as the honeybee and silkworm, are being
genetically engineered for disease resistance, and in the silkworm's
case, to produce proteins other than silk.9' Other insects are being
modified for the production of certain proteins in insect larvae. 2
Insects also may be modified for improved use in programs to try to
control other pest insects or invasive plant species.93 There will
likely be attempts to replace or infiltrate native populations of
insects with ones that have been genetically modified to be less of
a pest or unable to transmit pathogens.9 For instance, research is
ongoing to genetically modify mosquitos to make them malaria-
resistant.9 5
In sum, biotechnology-derived products hold enormous promise
for protecting human health and the environment, increasing
agricultural production, improving nutrition, and providing
economic benefits. In a world with resources constantly under
88. CASE STUDYNO. IV: FARM ANIMALTHAT PRODUCES HUMAN DRUGS, supra note 30, at
1; see also ANIMAL BIOTECHNOLOGY, supra note 27, at 16-17, 51-52 (discussing the production
of proteins in transgenic animal milk, eggs, or blood).
89. CASE STUDY NO. IV: FARM ANIMAL THAT PRODUCES HUMAN DRUGS, supra note 30,
at3.
90. ANIMAL BIOTECHNOLOGY, supra note 27, at 17. Transgenic pigs may prove a useful
source for organ transplants in humans. Currently, transplantation of pig organs in humans
is not possible in part because humans have a dramatic immune response to a carbohydrate
on the surface of pig cells. Inactivation of this enzyme in pigs through genetic modification
could solve this problem. Id. at 37.
91. Id. at 21; THE PEW INITIATIvE ON FOOD & BIOTECHNOLOGY, BUGS IN THE SYSTEM?:
ISSUES IN THE SCIENCE AND REGULATION OF GENETICALLY MODIFIED INSECTS (2004)
[hereinafter BUGS IN THE SYSTEM], available at http://pewagbiotech.org/researchlbugs/
bugs.pdf (last visited Apr. 7, 2004).
92. See ANIMALBIOTECHNOLOGY, supra note 27, at 21 (describing how private companies
already have begun to farm recombinant proteins from insect larvae).
93. Id.; BUGS IN THE SYSTEM, supra note 91.
94. ANIMAL BIOTECHNOLOGY, supra note 27, at 21, 81.
95. BUGS IN THE SYSTEM, supra note 91.
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greater and greater pressure, these potential advantages are far too
great to be ignored.
B. Potential Risks of Genetic Engineering
Despite the many potential benefits of genetic engineering
outlined in the preceding section, biotechnology does not come
without attendant potential risks. The risks from genetically
modified food generally can be divided into two categories: human
health impacts and environmental or ecological concerns.96 The
risks within each of these categories are discussed below, followed
by a section describing the potential new risks and concerns raised
by anticipated biotechnological advances.
1. Human Health Impacts
At the outset, it is important to note that there is no confirmed
case of human disease or illness caused by genetically modified
food.97 There are still several concerns about impacts related to
genetically modified food. From the human health perspective, the
main concerns are believed to be allergenicity and toxicity.98
Genes inserted into plants express proteins, and certain proteins
cause allergic reactions in some people.99 Allergic reactions can
96. A third category of issues raised by genetically modified products involves social and
ethical concerns that do not have human health or environmental consequences. These types
of concerns present normative issues, as opposed to scientific or objectively demonstrable
risks, and thus are outside the scope of this Article. Examples of such concerns include
potential industrialization or monopolization of agricultural business, whether the insertion
of certain genes violates religious or dietary restrictions, whether genetic engineering in the
first instance violates ethical norms, and whether genetically modified products should be
so labeled. On the last concern, note that the USDA's new National Organic Program food
labeling requirements may create an implicit "non-genetically modified" label because
products labeled "organic" cannot contain products produced through rDNA technology. See
National Organic Program, 7 C.F.R. § 205 (2003) (stating the requirements for organic
labeling).
97. See NRC 2000 REPORT, supra note 4, at 6-8 (discussing the potential human health
impacts and research needs related to genetically modified food).
98. Id. at 7.
99. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4709
(proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592); TEITEL & WILSON, supra
note 12, at 49. Approximately 5% to 8% of children and 2% of adults in the United States
suffer from food allergies. ANIMAL BIOTECHNOLOGY, supra note 27, at 68; Pollack, supra note
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range from relatively minor symptoms to serious harm, including
anaphylactic shock and death.'00 The amount of allergen exposure
necessary to cause a reaction, even a severe one, can be remarkably
small.101
Because allergenic proteins can be transferred by genetic
modification from one organism to another, 10 2 the introduction of
novel genetic material creates the possibility of introducing an
allergen into a genetically engineered product.0 3 This introduction
has occurred in at least one instance: a genetically modified soybean
expressed a protein from its donor organism (a brazil nut) that was
a known allergen.0 4 Similarly, new allergens could arise in the
pollen of genetically modified plants.0 5
As some of the genetic material transferred to create genetically
modified foods has never before been in the human diet, it is
impossible to know how humans will react.' 6 The National
Research Council has concluded that allergenicity is one of the most
54, at F2. Proteins found in cow's milk, soy, egg, wheat, and peanuts commonly induce
allergic responses in children; common adult allergens include fish, shellfish, tree nuts, corn,
and tomatoes. Oscar L. Frick, The Potential for Allergenicity in Transgenic Foods, in
GENETICALLY MODIFIED FooDs: SAFETY IssuEs 104 (Karl-Heinz Eagle et al., eds., 1995).
100. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. at 4728; see also
ROYAL SOC'YOF CAN., supra note 5, at 53-54 (describing the human body's response to food
allergies).
101. ROYAL SOC'YOF CAN., supra note 5, at 56-57 (one seventy-thousandth of a peanut can
cause a minor allergic reaction); TEITEL & WILSON, supra note 12, at 49.
102. ROYAL SOCY OF CAN., supra note 5, at 55.
103. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. at 4709.
104. NRC 2000 REPORT, supra note 4, at 66; ROYAL SOC'Y OF CAN., supra note 5, at 55. This
soybean was not commercialized. NRC 2000 REPORT, supra note 4, at 66; ROYAL SOC'Y OF
CAN., supra note 5, at 55. Although animal tests for allergenicity of the modified soybean
were negative, researchers found that humans allergic to brazil nuts also would be allergic
to the genetically modified soybean. ROYAL SOC'Y OF CAN., supra note 5, at 55. Tests for
allergenicity are not part of the standard testing of genetically modified products. Sheldon
Krimsky, Risk Assessment and Regulation of Bioengineered Food Products, 2 INT'L J.
BIOTECH. 231,236 (2000).
105. NRC 2000 REPORT, supra note 4, at 62-63.
106. Id. Indirect assessments-based on the source of the donor gene, comparison of the
donor protein with known allergens, immunologic analysis, and other factors-may be used
to provide insight into the potential for allergenicity to transgenic proteins new to the human
diet, but such assessments are not determinative. ROYAL SOC'YOF CAN., supra note 5, at 60-
61. The risk of allergenicity is particularly difficult to test, in part because prior exposure is
a prerequisite to an allergic reaction. NRC 2000 REPORT, supra note 4, at 66. The National
Research Council has recommended that priority be given to developing "improved methods
for identifying potential allergens in pest-protected plants." Id. at 7.
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difficult aspects in assessing the safety of transgenic products and
that the existing methods for identifying potential food allergens
are deficient.1 0 7 Further, even for proteins already in the human
diet, people who know they are allergic to certain foods may no
longer be able to avoid them because they will not know which
transgenic foods contain proteins that have been transferred."10
A second direct risk of human consumption of genetically
modified food is the possible introduction of new toxins, or increases
in the amounts of naturally occurring toxins.' 9 For instance,
certain conventionally bred crops have produced hybrids with toxins
not present in either parental line.'10 Genetically modified foods
also could contain less nutrients than their conventional counter-
parts.'
There is a potential risk of other types of health effects from the
consumption of genetically modified plants. One controversial study
found that rats fed genetically engineered potatoes had weakened
immune systems and changes in the development of multiple
organs." 2 The EPA has conducted fairly extensive short-term
testing with respect to pest-protected plants, and it has found no
adverse impact. 3 Some scientists still have concerns, however, and
the National Research Council has determined that the EPA does
not yet have enough data in this regard. 14
107. ANIMAL BIOTECHNOLOGY, supra note 27, at 68; NRC 2000 REPORT, supra note 4, at
140.
108. Sophia Kolehmainen, Precaution Before Profits: An Overview of Issues in Genetically
Engineered Food and Crops, 20 VA. ENVTL. L.J. 267, 278 (2001); McGarity, supra note 8, at
419. Relatedly, it may be hard to determine what is triggering the allergic reaction if the
genetic material causing it is present in a number of different foods. ROYAL Soc'Y OF CAN.,
supra note 5, at 56.
109. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4728
(proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592); NRC 2000 REPORT, supra
note 4, at 61-62, 70-71; ROYAL SOCkY OF CAN., supra note 5, at 46.
110. NRC 2000 REPORT, supra note 4, at 70; ROYAL SOC'Y OF CAN., supra note 5, at 16.
111. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. at 4728. One study
found that certain genetically modified soybeans contained less nutrients associated with
protection against heart disease, osteoporosis, and breast cancer than their conventional
counterparts; other studies have not confirmed these results. TEITEL & WILSON, supra note
12, at 12, 50-51.
112. TEITEL & WILSON, supra note 12, at 55. The commission that initially sponsored this
study fired the scientist who conducted it and stated that the research was deficient; a later
panel of independent scientists, however, confirmed the original findings. Id.
113. NRC 2000 REPORT, supra note 4, at 65-66.
114. McGarity, supra note 8, at 417-18.
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The risks identified in the preceding paragraphs are all direct
human health risks. There are also indirect risks. In order to
determine whether genetically modified cells have successfully
incorporated the desired donor gene, scientists often attach an
additional DNA fragment to the donor gene before it is inserted into
the target host cell. This additional fragment contains a gene that
will render the host cell resistant to a particular antibiotic. The
potential transgenic cells are then exposed to this antibiotic, and
those that have not successfully incorporated the donor gene will
die off, leaving only genetically modified cells.115 The surviving,
modified cells are grown into modified plants, which still will
contain the antibiotic-resistant trait. There is a concern that this
antibiotic-resistant gene could be transferred to other organisms,
or carried up the food chain into animals or people who eat the
plant product.116 The result could be a strain of bacteria that is
resistant to one or more antibiotics." 7 This is of particular concern
because of the general growing problem of bacterial resistance to
antibiotics."' Both the Canadian Royal Society and the British
Medical Association have recommended the cessation of the use of
antibiotic marker genes in genetically modified food." 9
Finally, the last risk is one that transcends categorization:
genetic modification of food has the potential for unintended genetic
consequences. This can occur for two primary reasons. First, gene
insertion into host cells is an inexact process. Scientists cannot yet
determine or predict the position of the inserted genetic matter
in the host gene, and it varies from one insertion to the next. As a
result, identical genetic modifications can affect cellular function
in different ways. 20 Second, one cannot know what pleiotropic121 or
115. TEITEL & WILSON, supra note 12, at 8-9.
116. NRC 2000 REPORT, supra note 4, at 63; TEITEL & WILSON, supra note 12, at 39; Julie
Teel, Regulating Genetically Modified Products and Processes: An Overview of Approaches,
8 N.Y.U. ENVTL. L.J. 649, 659 (2000).
117. McGarity, supra note 8, at 403, 423.
118. Kolehmainen, supra note 108, at 277. Though antibiotic resistance is a general
concern in society, the risk of antibiotic resistance arising out of genetically modified foods
is likely far lower than the risks posed by the large uses of antibiotics to prevent disease in
livestock and human medicine. ROYAL SOC'Y OF CAN., supra note 5, at 49.
119. ROYAL SOC'Y OF CAN., supra note 5, at 49; McGarity, supra note 8, at 403, 424.
120. Krimsky, supra note 104, at 233; see also NRC 2000 REPORT, supra note 4, at 61, 66.
121. "Pleiotropic" effects are unintended genetic changes that result from the inserted
genetic material having an effect beyond that intended on traits of the host organism.
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synergistic effects may be caused by combining genes. 12 For
instance, there are many examples of conventional breeding
projects that have resulted in hybrid offspring with traits that were
unexpected based on knowledge of the parents' genes. 1
23
In sum, genetic engineering of crops raises several direct and
indirect potential human health concerns.
2. Environmental and Ecological Concerns
Genetically modified plants may impact the environment
negatively through several mechanisms.' 24 First, newly introduced
genetic material may move into environments or organisms beyond
those intended. This gene flow could occur through the dispersal of
genetically modified seeds; through the dispersal of the pollen of a
genetically modified plant by wind, animals, bees, or insects; or
through the nonsexual transfer of genetic material from one
organism to another, for instance, by virus or bacteria ("horizontal
transfer").125 The risk of gene flow is considered a "major environ-
mental concern." 2 ' According to the National Research Council,
"the introduction of any type of biological novelty can have unin-
tended and unpredicted effects on the recipient community and
122. Krimsky, supra note 104, at 233,235; see also NRC 2000 REPORT, supra note 4, at 61,
66; TEITEL & WILSON, supra note 12, at 12. Examples of the imprecision in genetic
engineering to date include: (1) genes for the color red placed into petunias not only changed
the petunias' color, but also decreased their fertility and altered their growth, and (2) salmon
genetically engineered with a growth hormone gene not only grew too big too fast, but also
turned green. TEITEL & WILSON, supra note 12, at 12.
123. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4710
(proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592); NRC 2002 REPORT, supra
note 2, at 43. In one example, a cross between two potato species created a hybrid offspring
that produced a novel steroidal alkaloid not produced by either parent. NRC 2002 REPORT,
supra note 2, at 43.
124. Agriculture was not benign with respect to the environment prior to the advent of
transgenic crops. Examples of substantial environmental impacts from conventional
agriculture include the destruction of forests and natural habitats, contamination from
pesticide and herbicide residues, and the loss of biodiversity. See Guruswamy, supra note 46,
at 474.
125. NRC 2002 REPORT, supra note 2, at 66-67; NRC 2000 REPORT, supra note 4, at 80;
TEITEL & WILSON, supra note 12, at 38-39. Organic farmers particularly are concerned about
gene flow because the movement of genes from genetically modified plants into organic crops
could render such crops nonorganic. NRC 2000 REPORT, supra note 4, at 90.
126. ROYAL SOCY OF CAN., supra note 5, at 124.
2194 [Vol. 45:2167
2004] GENETICALLY MODIFIED PLANTS AND ANIMALS
ecosystem."'27 The environmental risk from gene flow will increase
as the quantity and variety of genetically modified plants expand. 1
28
If, for instance, herbicide-tolerant genes spread from engineered
crops to a weedy relative, "superweeds" not susceptible to herbicides
may be created. 129 Long-distance pollen flow, and therefore long-
distance gene flow, is poorly understood, but transgenic pollen has
dispersed at least three or four kilometers from its source.3 0 The
National Research Council noted that "the potential for enhanced
weediness is the major environmental risk perceived for introduc-
tions of genetically modified plants,"'' and has called for more
research in this area.1 2 Relatedly, species that are not currently
considered weeds could become more difficult to control if they
acquire certain transgenic traits.1
3
The risk of gene flow is not merely theoretical. In Britain, an
experimental field of transgenic herbicide-tolerant plants were
found to have pollinated nearby conventional plants.'3 4 In Canada,
a variety of canola found growing as a weed was discovered to
have acquired resistance to three different herbicides through
gene flow.' 35 Similarly, conventional crop genes are known to have
spread to wild populations, sometimes creating more robust and
abundant weeds, 31 and some experiments have indicated that
genetically engineered plants may be more likely to cross-pollinate
than their conventionally bred counterparts.3 7 Such a risk was
127. NRC 2002 REPORT, supra note 2, at 29.
128. Proposed Field Test Requirements, supra note 21, 67 Fed. Reg. at 50,578.
129. See NRC 2002 REPORT, supra note 2, at 67.
130. ANDERSON, supra note 24, at 49; NRC 2000 REPORT, supra note 4, at 91. Most pollen
is dispersed only a short distance from the plant. ROYAL SOC'Y OF CAN., supra note 5, at 124.
131. NAT'L RESEARCH COUNCIL, FIELD TESTING GENETICALLY MODIFIED ORGANISMS:
FRAMEWORK FOR DECISIONS 3 (1989).
132. NRC 2000 REPORT, supra note 4, at 141.
133. Id. at 81.
134. John Charles Kunich, Mother Frankenstein, Doctor Nature, and the Environmental
Law of Genetic Engineering, 74 S. CAL. L. REV. 807, 817-18 (2001).
135. THE PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, HAVE TRANSGENES WILL TRAVEL:
ISSUES RAISED BY GENE FLOW FROM GENETICALLY ENGINEERED CROPS (2003).
136. NRC 2002 REPORT, supra note 2, at 67; see also NRC 2000 REPORT, supra note 4, at
84.
137. Kolehmainen, supra note 108, at 276 (discussing these experiments with genetically
engineered mustard plants).
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determined to exist for a genetically modified virus-resistant
squash approved by the USDA."18
A derivative risk of gene flow is the potential extinction of wild
species through hybridization." 9 If genes from transgenic crops find
their way into wild plant species through asexual transfer or
interbreeding, and the wild transgenic plants then interbreed with
unmodified plants, the result could be extinction of the unmodified
wild species.
A second route of environmental impact from genetically
engineered plants is through the spread of nonindigenous trans-
genic species into natural habitats, which also could cause the
extinction of a wild species or other disruption of ecosystems.
140
The introduction of invasive species poses a serious threat to
biodiversity."'4 Invasive species cost the United States an estimated
$137 billion annually, 142 and are second only to habitat destruction
in threatening the extinction of native species. 143 It is anticipated
that additional risks may arise as the frequency and scale of the
introduction of transgenic species increase.
144
Genetically modified herbicide-tolerant canola plants, for
example, are beginning to develop into a major weed problem in
138. NRC 2002 REPORT, supra note 2, at 130-35.
139. Id. at 67-68, 134-35. Extinction through hybridization has been implicated in the
disappearance of wild coconuts and the contamination of California's wild walnut populations
with genes from cultivated species. Id. at 68.
140. Id. at 68-70; Wolfenbarger & Phifer, supra note 57, at 2088.
141. Press Release, USDA, President Clinton Expands Federal Effort To Combat Invasive
Species (Feb. 3, 1999) [hereinafter USDA Press Release], available at http://www.usda.gov/
news/releases/1999/02/0043 (last visited Apr. 7, 2004); see also Wolfenbarger & Phifer, supra
note 57, at 2088 ("[llnvasive species have been categorized as one of the three most pressing
environmental problems, in addition to global climate change and habitat loss.").
142. Wolfenbarger & Phifer, supra note 57, at 2088 (explaining that these expenses result
from "direct and indirect effects, and control or preventive measures" of invasive species).
143. See USDA Press Release, supra note 141 (stating that "the spread of exotic species
constitutes one of the most serious, yet least appreciated, threats to biodiversity"). The
factors that cause one nonindigenous species to be harmless or beneficial, but another one
to become problematically invasive are not well known. NRC 2002 REPORT, supra note 2, at
207; see also Wolfenbarger & Phifer, supra note 57, at 2088-89. The majority of introduced
species do not become established long term. About "10% of intentionally introduced species
persist after introduction," and of these "roughly 10% become an obvious problem." NRC 2002
REPORT, supra note 2, at 32. Approximately one percent of introductions, thus, become
problematic. "The small fraction ... that do cause environmental effects can be tremendously
disruptive ..... Id.
144. Wolfenbarger & Phifer, supra note 57, at 2090.
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some parts of Canada. 14 Further, some of these weed-plants have
been found to have acquired multiple herbicide-tolerant transgenes
from different genetically engineered plants.
14
Relatedly, there is concern that widespread success of geneti-
cally modified plants will lead to greater uniformity, and conversely
less biodiversity, in the farm crop. This in turn will make the
country more susceptible to widespread crop failures and other crop
disturbances.
14 7
The third mechanism of environmental impact is hazards to
nontarget species. For example, pest-protected plants may be toxic
to insects and animals other than those targeted by the introduced
pesticide.'I  One of the benefits of transgenic crops identified
earlier is the reduction of pesticide residue in the environment. 1
49
The converse of this benefit is that rather than having the
pesticide applied at limited intervals, it is now contained in the
modified plant throughout the entire growing season. This may
make the pesticide more persistent in the environment, particu-
larly in soils, than sprayed pesticides that decay rapidly and
are only used at times or during years when certain insects
are particularly problematic. 150 Greater exposure to a pesticide
145. ROYAL SOC'Y OF CAN., supra note 5, at 122.
146. Id. Overall, the likelihood of genetically modified crops becoming serious invasive
problems may be remote because most major crop species are artificially selected over time
for traits that have low survival value in natural conditions. Id. at 121. Crop plants, thus,
rarely disturb natural plant communities. Id.
147. Holly Saigo, Agricultural Biotechnology and the Negotiation ofthe Biosafety Protocol,
12 GEO. INV'L ENVTL. L. REV. 779, 793-96 (2000). The most familiar example of widespread
crop failure is the Irish Potato Famine of 1845. One million people (12% of the population)
died of starvation as a result of a potato blight that destroyed the genetically uniform
(monoculture) Irish potato crop. Id. at 795-96; TEITEL & WILSON, supra note 12, at 17, 97-98.
The risk of monoculture is demonstrated by the fact that the same potato blight also struck
in the Andes, but only affected a few of the forty-six varieties of potato grown there, and thus
was not as destructive. ANDERSON, supra note 24, at 53. Instances of modern impacts from
genetic uniformity exist in the United States. In 1970, there was widespread failure of the
American corn crop due to Southern Corn Leaf Blight, which affected multiple varieties of
corn with an identical gene. Saigo, supra, at 796; see also TEITEL & WILSON, supra note 12,
at 98-99.
148. CASE STUDYNO. II: BT-MAIZE, supra note 36, at 25. There is some evidence of impacts
on lacewings and Monarch butterflies. See NRC 2002 REPORT, supra note 2, at 70-71
(discussing lacewings); see also infra Part III.C (discussing Monarch butterflies).
149. See supra Part II.A.3.
150. See NRC 2002 REPORT, supra note 2, at 71; NRC 2000 REPORT, supra note 4, at 101;
TEITEL & WILSON, supra note 12, at 54; Wolfenbarger & Phifer, supra note 57, at 2089. This
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increases the probability that pests will evolve to overcome the
protection mechanism, rendering the pesticide useless.' 5 ' On the
other hand, this impact may be lower than the impacts of tradi-
tional insecticides because traditional insecticides are broad
spectrum, and therefore the transgenic pest-protected plants could
lead to greater biodiversity in agricultural ecosystems where they
replace certain traditional insecticides.
152
Use of herbicide-tolerant crops also could have negative environ-
mental consequences, as growers may increase herbicide applica-
tions because the crops are not affected by the herbicide." 3 Not only
would this increase contamination, but also increased applications
appear to be leading to the development of herbicide-tolerant
weeds, thus requiring application of more herbicides." 4 It is
estimated that extra herbicide use may increase weed control costs
as much as one hundred percent in some cases.'55 In addition to
leaving greater herbicide residue in the environment, more effective
control of weeds also could lead to reduced biodiversity and to lower
food availability for seed-specializing animals, particularly certain
birds. 156
route of pesticide exposure in the soil is new, and the effects on microorganisms are
unknown. ROYAL SOC'Y OF CAN., supra note 5, at 110.
151. NRC 2000 REPORT, supra note 4, at 19,28; ROYAL SOCYOF CAN., supra note 5, at 139;
TEITEL & WILSON, supra note 12, at 27-28. Instances of pest adaptation to conventional Bt
products have been documented, and insect resistance to Bt crops is considered inevitable.
NRC 2002 REPORT, supra note 2, at 76; NRC 2000 REPORT, supra note 4, at 35. This is
particularly problematic for organic farmers, as Bt pesticides represent one of the few
effective organic means to control pests. NRC 2000 REPORT, supra note 4, at 101; ROYAL
SOC'YOF CAN., supra note 5, at 139. The EPA is attempting to inhibit the development ofpest
resistance to Bt pesticides through the use of refuge zones-plantings of non-Bt crops that
are not sprayed with conventional Bt. Rebecca Bratspies, The Illusion of Care: Regulation,
Uncertainty, and Genetically Modified Food Crops, 10 N.Y.U. ENVTL. L.J. 297, 327 (2002).
The integrity of this program and its likelihood of success are questionable. See id. at 327-47
(discussing numerous problems with the EPA's refuge plan); see also GREGORY JAFFE,
PLANTING TROUBLE: ARE FARMERS SQUANDERING BT CORN TECHNOLOGY?. 5 (2003), available
at http://www.cspinet.org/new/pdf/bt corn.report.pdf (last visited Apr. 7, 2004) (reporting
that 19% of growers do not comply with the EPA's refuge requirements and 13% of growers
do not plant refuges at all).
152. NRC 2000 REPORT, supra note 4, at 9, 80.
153. Pimentel, supra note 52, at 57, 63.
154. See Andrew Pollack, Widely Used Crop Herbicide Is Losing Weed Resistance, N.Y.
TIMES, Jan. 14, 2003, at C1.
155.. Pimentel, supra note 52, at 63.
156. NRC 2002 REPORT, supra note 2, at 76; see also ANDERSON, supra note 24, at 27;
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Overall, genetically modified products raise substantial environ-
mental and ecological concerns due to potential gene flow, through
the introduction of nonindigenous species, and from hazards to
nontarget species.
3. Next-Generation Biotechnology Concerns
Not surprisingly, the future advances in biotechnology that
promise spectacular benefits also bring additional potential risks.
The National Research Council has determined that the environ-
mental risks of future transgenic plant varieties and their novel
traits cannot be predicted, and are of a"wholly different order" than
those posed by currently commercialized transgenic crops. 157 The
introduction of transgenic plants tolerant to extreme temperatures,
soil conditions, or climates, for example, could have impacts on
other plant communities.'58
The growth of pharmaceuticals or industrial compounds in plants
raises fresh concerns beyond those discussed with respect to
genetically modified crop plants, including enhanced concerns about
the need for confinement and protection of the food supply.
5 9
Pharmaceutical-producing or industrial compound-producing plants
could get into the general food supply through multiple routes: the
crops or seeds could be misrouted during processing, pollen from a
transgenic crop could fertilize a nearby food crop, insects could eat
the modified plants, or the drug or compound could leak from the
roots into the soil. 6 ° Additional risks include a pharmaceutical
Wolfenbarger & Phifer, supra note 57, at 2089.
157. NRC 2002 REPORT, supra note 2, at 229-30, 246.
158. Id. at 230-3 1.
159. No products from pharmaceutical plants have yet completed the regulatory process
in the United States. CASE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN, supra note 73, at
47. Some conventional plants have pharmaceutical properties, but the anticipated level of
expression and concentration of the pharmaceutical in, as well as the wide-spread production
and planting of, genetically modified plants raises new levels of concern. Id.
160. NRC 2002 REPORT, supra note 2, at 66-67; see also CASE STUDY No. III: HERBICIDE-
TOLERANT SOYBEAN, supra note 73, at 47-49; Pollack, supra note 22. One advantage of using
tobacco plants to grow pharmaceuticals is that few organisms feed on them, likely because
of the production of nicotine. Id. at 52. In particular, no mammals or birds feed on tobacco
plants, earthworm populations are low in tobacco fields, and the tobacco plants are
deflowered or harvested before flowering so bees and other pollinators should not visit the
plants and should not be affected. Id.
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itself being contaminated by pesticides or chemicals naturally
occurring in plants (such as nicotine impacting pharmaceuticals
grown in tobacco plants), or allergic reactions being caused by the
transfer of proteins from the plants into pharmaceuticals.'61 As the
National Research Council has concluded, the "production of
nonedible and potentially harmful compounds in crops ... that have
traditionally been used for food creates serious regulatory issues.' 62
The development of genetically modified animals raises multiple
new risks, the greatest of which is the potential impact on the
environment from the escape or release of transgenic animals.
163
Escapes of transgenic fish and shellfish are considered inevitable,
and could overwhelm and potentially cause the extinction of wild
species through two routes. 164 First, escaped transgenic fish could
out-compete wild fish for resources such as food, space, and mates,
particularly if the transgenic fish have been modified to improve
fitness, adaptability, or survival traits.165 Escaped farmed fish, for
example, have destroyed egg nests constructed by their wild
counterparts. 166 Second, escaped transgenic fish may threaten wild
fish populations through hybridization. Escapes of nontransgenic
farmed fish have been known to spawn successfully with wild
relatives, 167 and studies have shown that populations of wild fish
can "be wiped out by mating with certain kinds of genetically
engineered fish."168 There is also the previously discussed risk of
161. Pollack, supra note 22.
162. NRC 2002 REPORT, supra note 2, at 229.
163. As this Article goes to press, the National Research Council is releasing a new report
on biological techniques to prevent genetically modified organisms from escaping into natural
ecosystems and breeding or competing with their wild relatives, or passing engineered traits
on to other species. NAT'L RESEARCH COUNCIL, BIOLOGICAL CONFINEMENT OF GENETICALLY
ENGINEERED ORGANISMS (2004).
164. ANIMAL BIOTECHNOLOGY, supra note 27, at 30, 90-92; CASE STUDY NO. I: GROWTH-
ENHANCED SALMON, supra note 81, at 6.
165. ROYAL SOC'Y OF CAN., supra note 5, at 154-56; see also ANIMAL BIOTECHNOLOGY,
supra note 27, at 76-78.
166. ROYAL SOC'Y OF CAN., supra note 5, at 156.
167. CASE STUDYNO. I: GROWTH-ENHANCED SALMON, supra note 81, at 5; ROYAL SOC'YOF
CAN., supra note 5, at 156.
168. Carol K. Yoon, Altered Salmon Leading Way to Dinner Plates, but Rules Lag, N.Y.
TIMES, May 1, 2000, at Al; see also CASE STUDY NO. I: GROWTH-ENHANCED SALMON, supra
note 81, at 6-7.
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unpredictable environmental disruptions that can arise whenever
nonindigenous species invade an ecosystem. 16 9
Escapes of transgenic insects are almost inevitable. Insects used
for biocontrol would be intentionally released into the environment
to control insect pests or invasive plants. This raises concerns
regarding the transfer of introduced genes to wild populations of
the same or other insects, extinction or other impacts on native
species, and disruption of ecosystems. 170 Escapes of genetically
engineered farm animals could present similar concerns to those
posed by fish and insects, but the likelihood of escape is consider-
ably lower.1
71
Bioengineered farm animals create other novel hazards. Trans-
plantation of animal organs into humans may allow for the
transmission of infectious disease and the creation of new disease
agents.'72 A pathogenic virus could be created in the transgenic
animal from the combination of genetic material used to insert the
transgene and nonpathogenic viruses already present in the host
animal. 7 ' The development of disease-resistant animals could
create future difficulties in disease control and transmission of
disease to other species, including humans.
174
Transgenic animals also cause concerns for the human food
supply. As with plants, genetically modifying animals will result in
the expression of new proteins, raising the risk of an allergenic
response by certain consumers or the creation of toxins in the
animal meat. 175 Some scientists are concerned that genetically
engineered fish may bioaccumulate higher levels of toxins in their
169. CASE STUDYNO. I: GROWTH-ENHANCED SALMON, supra note 81, at 6-7,24. Transgenic
animals in particular may have unexpected ecological impacts associated with their fitness,
interaction with other animals, roles in ecosystem processes, or potential for dispersal and
persistence. Id. at 22; see also ANIMAL BIOTECHNOLOGY, supra note 27, at 78.
170. ANIMAL BIOTECHNOLOGY, supra note 27, at 21, 88; BUGS IN THE SYSTEM, supra note
91.
171. CASE STUDY No. IV: FARM ANIMAL THAT PRODUCES HUMAN DRUGS, supra note 30,
at 8.
172. ANIMAL BIOTECHNOLOGY, supra note 27, at 56-60.
173. Id. at 52.
174. ROYAL SOC'Y OF CAN., supra note 5, at 93; see also ANIMAL BIOTECHNOLOGY, supra
note 27, at 47.
175. ANIMAL BIOTECHNOLOGY, supra note 27, at 68-69, 71.
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tissues than conventional fish, posing a health concern for humans
or animals that eat the fish.1
7 6
Animals genetically engineered for nonfood products present
additional hazards.'77 For instance, animals modified to produce
proteins or other products will not be intended for human consump-
tion, and adequate control measures will need to be established to
ensure that they do not end up in the food supply.
178
Genetically engineering animals raises some concerns for the
animals themselves. For instance, pleiotropic effects (such as
changes in anatomy, behavior, and enzyme and hormonal activity),
are quite common in genetically engineered fish, and have been
observed in modified farm animals as well. These effects can lead
to physical or psychological suffering for the animal.
179
Next-generation biotechnology poses risks of both a different
magnitude and a different kind than existing genetically modified
food crops.
To summarize, genetic engineering holds the prospect of spectac-
ular health, environmental, and economic benefits for society, but
these benefits do not come risk-free. In order to maximize the social
benefit from biotechnology, it is necessary to establish a comprehen-
sive, efficient, scientifically rigorous regulatory system to ensure
adequate protection of human health and the environment. To
determine how to institute such a system, it is useful first to
examine several situations in which the regulation of biotechnology
products has proven deficient.
III. GENETICALLY MODIFIED PRODUCT CASE STUDIES
Over the past several years, a number of incidents involving
genetically modified products have occurred that highlight the need
for proper regulation. First, proper regulation is necessary to limit
the potential risks to human health and the environment resulting
176. FUTURE FISH, supra note 25, at 31. There is a concern that genetically modified fish
could produce novel toxins, but some scientists argue that this is unlikely. Id.
177. ANIMAL BIOTECHNOLOGY, supra note 27, at 65.
178. Id. at 54, 65-67. For animals modified to produce proteins in milk or eggs, "[h]alf of
the genetically engineered population will be male, and will not be directly useful in
production," and producers therefore will seek other manners of use. Id. at 66.
179. ROYAL SOCY OF CAN., supra note 5, at 87, 91-92; see also ANIMAL BIOTECHNOLOGY,
supra note 27, at 43-44, 98.
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from the development and commercialization of genetically modified
products. Second, the widespread media and popular attention paid
to these incidents can cause or increase public distrust concerning
genetically modified products, which in turn may limit society's
ability to reap the full benefits of this still-nascent technology.'
A. StarLink Corn
Probably the best known genetically modified food scare was the
discovery of StarLink corn, a genetically engineered strain of corn
not approved for human consumption, in human food in the fall of
2000.181 StarLink corn was not approved for human consumption
because it carried transgenic genes that expressed a protein
containing some attributes of known human allergens. 2 Because
these proteins were never a part of the human diet before, it was
unknown whether they would cause severe and potentially life-
threatening allergic reactions in some humans.' 3
In 1998 the EPA approved Aventis CropScience's registration
of StarLink corn for commercial use as animal feed,' 8 ' and for
nonfood industrial uses, such as in ethanol production.' Aventis
CropScience requested approval for use in human food, and
resubmitted such a request to the EPA in 1999. A series of tests by
the EPA found that it was not possible to determine whether
StarLink might trigger food allergies. As a result, the EPA did not
approve StarLink corn for human consumption.'8 6 An independent
180. Gregory N. Mandel, Building Confidence Through Teamwork on Regulatory
Proposals: The Genetically Modified Product Model, 44 JURIMETRICS J. 41, 50-54 (2003).
181. In re StarLink Corn Prods. Liab. Litig., 212 F. Supp. 2d 828 (N.D. Ill. 2002).
182. Id. at 834.
183. See Barnaby J. Feder, Companies Act To Keep Bioengineered Corn Out of Food, N.Y.
TIMES, Sept. 27, 2000, at C2. Since Cry9C, the bacterial protein found in the StarLink corn,
was never before a part of the human diet, there was no way to conduct a conclusive allergy
test. Andrew Pollack, Kraft Recalls Taco Shells That Contain Bioengineered Corn, N.Y.
TIMES, Sept. 23, 2000, at C1.
184. Sutter v. Aventis CropScience USA Holding, Inc., 145 F. Supp. 2d 1050, 1052 (S.D.
Iowa 2001).
185. In re StarLink Corn, 212 F. Supp. 2d at 834.
186. Id.; EPA, WHITE PAPERON THE POSSIBLE PRESENCE OFCRY9C PROTEIN INPROCESSED
HUMAN FOODS MADE FROM FOOD FRACTIONS PRODUCED THROUGH THE WET MILLING OF CORN
1 (Mar. 7, 2001) [hereinafter WHITE PAPER: WET MILLING CORN], available at httpJ/
www.epa.gov/oppbppdl/biopesticides/pips/wetmill18.pdf (last visited Apr. 7, 2004).
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Scientific Advisory Panel later convened by the EPA concluded that
StarLink was a potential food allergen, and that no safe threshold
level could be established."17
Because of the limited approval, the EPA required special
procedures for StarLink corn. These procedures included: "manda-
tory segregation methods to prevent StarLink from commingling
with other corn"; a "'buffer zone' around StarLink corn crops to
prevent cross-pollination"; and requirements that Aventis inform
growers of the EPA restrictions and have the growers sign an
agreement outlining management requirements.'
In September 2000, StarLink corn was discovered in Kraft Foods'
Taco Bell-brand taco shells.189 As a result, Kraft Foods ordered a
recall of more than 2.5 million boxes of taco shells and halted
production of the Taco Bell-brand shells.190 The recall cost Kraft
Foods millions of dollars.' 9' StarLink corn was later found in many
other brands of taco shells and other human food products as well,
resulting in the eventual recall of over three hundred products.'92
Azteca Mills, the company that milled the Kraft Food shells,
halted further shipments of certain corn products from the mills
identified as the sources of corn meal in the Kraft shells. 9 ' The
Taco Bell restaurant chain decided to replace the shells in all 7000
of its restaurants. 94 Kellogg, ConAgra, and Archer Daniels Midland
were all forced to stop production at certain plants because of
concerns about StarLink contamination.'9 5 Shipments of U.S. corn
187. Press Release, EPA Scientific Advisory Panel, Scientific Report on StarLink Corn
Available (July 27, 2001) [hereinafter EPA Scientific Report), available at httpJ/www.epa.
gov/scipoly/sap/pressrelease72701.htm (last visited Apr. 7, 2004); see also In re StarLink
Corn, 212 F. Supp. 2d at 835.
188. In re StarLink Corn, 212 F. Supp. 2d at 834-35.
189. Feder, supra note 183, at C2. The StarLink corn was discovered by an anti-genetic
engineering advocacy group; there is no postmarket monitoring of genetically modified
products in food. TAYLOR & TICK, supra note 20, at 39.
190. Feder, supra note 183, at C2.
191. Id.
192. ALEJANDRO E. SEGARRA & JEAN M. RAWSON, CRS REPORT RS20732, STARLINK CORN
CONTROVERSY: BACKGROUND (Jan. 10, 2001), available at http://www.ncseonline.org/nle/
crsreports/agricultureag-101.cfm (last visited Apr. 7, 2004); TEITEL & WILSON, supra note
12, at 29, 159.
193. Feder, supra note 183.
194. Pollack, supra note 183.
195. TAYLOR & TICK, supra note 20, at 78; James Cox, StarLink Fiasco Wreaks Havoc in
the Heartland: Developer Wants EPA To Approve Seed for Food Supply, USA TODAY, Oct. 27,
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were turned away from Japan and South Korea after testing
revealed contamination with StarLink corn, leading to a sharp
reduction in corn exports from the United States and costing
United States farmers tens of millions of dollars. 96 Grain eleva-
tors and transporters were forced to institute expensive tests on
corn shipments to assure that they were not contaminated.
197
Aventis CropScience agreed to buy back the year's entire crop of
StarLink corn, at a cost of about $100 million, in an effort to
prevent the grain from further contaminating the food supply."' It
was anticipated that StarLink-related costs could end up running
as high as $1 billion.199
At the urging of the EPA, Aventis CropScience voluntarily agreed
to cancel its StarLink registration, thus prohibiting StarLink corn
from being planted for any reason. 00 Aventis CropScience stated
that "it would no longer market bioengineered products for any use
until they had been cleared for use in human food."2' The EPA
stated that "it would no longer grant 'split' approvals for genetically
modified crops."20 2
2000, at lB.
196. TAYLOR & TICK, supra note 20, at 78; see also In re StarLink Corn Prods. Liab. Litig.,
212 F. Supp. 2d 828, 835 (N.D. Ill. 2002); Dupraz v. Aventis CropScience Holding, Inc., 153
F. Supp. 2d 1102,1103 (D.S.D. 2001); PAUL MCAULIFFE, WORLD COMMODITYANALYSIS CORP.
STARLINK CORN A PROBLEM FOR U.S. CORN EXPORTS? (2001), at http://www.biotech-
info.net/problem.html (last visited Apr. 7, 2004); Charles A. Deacon & Emilie K Paterson,
Emerging Trends in Biotechnology Litigation, 20 REV. LITIG. 589, 614 (2001).
197. In re StarLink Corn, 212 F. Supp. 2d at 835.
198. Andrew Pollack, European Company Will Buy Entire Crop of Corn in Recall, N.Y.
TIMES, Sept. 30, 2000, at C14. Aventis CropScience later stated that it had "located 88% of
the [2000] StarLink harvest and contained it on farms where it was grown," but that nine
million bushels remained unaccounted for. Cox, supra note 195.
199. Cox, supra note 195.
200. In re StarLink Corn, 212 F. Supp. 2d at 835; WHrrE PAPER: WET MILLING CORN, supra
note 186, at 1; Andrew Pollack, Aventis Gives Up License To Sell Bioengineered Corn, N.Y.
TIMES, Oct. 13, 2000, at C5. Aventis CropScience, backed by the food industry, asked the
EPA to permit the use of StarLink corn in food for four years in order to prevent a
widespread disruption of the food and grain industries, because that was how long it was
expected for the existing StarLink corn to work its way through the system. Andrew Pollack,
Corn Developer Appeals to E.P.A., N.Y. TIMES, Oct. 26, 2000, at C4.
201. Feder, supra note 183. In the spring of 2001, Aventis announced that it was looking
for buyers for Aventis CropScience, Aventis' agrochemicals subsidiary. Deacon & Paterson,
supra note 196, at 615.
202. TAYLOR & TICK, supra note 20, at 78.
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A number of people complained of adverse reactions from eating
food products containing StarLink corn.2"' The Centers for Disease
Control investigated some of these reports but "did not find any
evidence that hypersensitivity to the [transgenic] Cry9C protein [in
StarLink corn] was responsible for the self-reported allergic
responses."0 4 A class action lawsuit was filed by citizens alleging
allergic reactions to taco shells containing StarLink corn.
20 5
Numerous class actions were filed against Aventis CropScience
on behalf of growers alleging that their corn crop was contaminated
by StarLink corn or that they were injured by the widespread
decline in corn demand.206 Nationwide and statewide class action
lawsuits were consolidated into a multidistrict litigation in In re
StarLink Corn Products Liability Litigation.°7 Certain of these
lawsuits have been settled for over $100 million. °8
StarLink corn was planted in twenty-nine states in 2000.209 In
early 2001, the USDA announced that StarLink corn had been
detected in non-StarLink seed intended for sale that year. It was
anticipated that all StarLink corn would be removed from the corn
203. Press Release, Centers for Disease Control and Prevention, Backgrounder: CDC
Involvement in Investigating Adverse Health Effects Associated with Eating Corn Products
Potentially Contaminated with the Cry9C Protein in StarLink Corn (June 13, 2001),
available at http:/Iwww.cdc.gov/od/oc/media/pressrel/r0l06l3a.htm (last visited Apr. 7,2004).
204. Id.
205. Deacon & Paterson, supra note 196, at 614.
206. In re StarLink Corn Prods. Liab. Litig, 212 F. Supp. 2d 828, 842-43 (N.D. Ill. 2002);
Deacon & Paterson, supra note 196, at 614-15. The contamination class actions were based
both on cross-pollination in the field and contamination by commingling in the distribution
process. In re StarLink Corn, 212 F. Supp. 2d at 842-43.
207. In re StarLink Corn, 212 F. Supp. 2d at 833.
208. See Allison Beers, Food, Biotech Firms Settle StarLink Consumer Lawsuit, FOOD
CHEM. NEWS, Mar. 11, 2002, at 1 (reporting approval of a $9 million settlement in a
consumer class action lawsuit against companies that produced and sold StarLink corn);
BiotechII:; StarLink Creator, DistributorAgree to$110M Settlement, GREENWIREFeb. 7,2003
(reporting that the developer and distributor of StarLink corn agreed to pay farmers $110
million to settle the farmers' claims that they had not been properly informed that StarLink
corn had not been approved for human consumption); Stephen Clapp, StarLink Settlement
Approved by Judge, FOOD CHEM. NEWS, Apr. 14, 2003, at 6 (reporting final approval of $110
million settlement for farmers whose property was contaminated by StarLink corn or who
were injured by a reduction in corn prices because of the StarLink corn contamination).
209. Cox, supra note 195.
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grain supply by 2002.21 ° On December 27, 2002, Japanese authori-
ties found "traces of StarLink corn in a shipment from the U.S."21'
Several final points should be noted on this case study. The
harvesting, storage, shipping, and processing equipment are often
the same for human and animal food. Corn from myriad farms is
commingled as it is gathered, stored and transported.212 Conse-
quently, StarLink corn was commingled with human food corn in
numerous grain elevators. 21" Due to recognized commingling, the
agricultural industry accepts about 2-7% foreign matter in bulk
shipments of corn in the United States.214 The StarLink corn-
contaminated taco shells contained only about 1% StarLink corn.215
Further, it was later discovered that growers of StarLink corn had
been inadequately warned about the need to keep it segregated
from other corn.216
Someone with working knowledge of the country's agricultural
system would have recognized from the outset that it was inevitable
that once StarLink corn was grown, produced, and processed on a
large-scale basis, some of it would make its way into the human
food supply.217 According to one agricultural expert, "Anyone who
understands the grain handling system... would know that it would
be virtually impossible to keep StarLink corn separate from corn
that is used to produce human food ....
210. EPA Scientific Report, supra note 187.
211. TAYLOR & TICK, supra note 20, at 93.
212. In re StarLink Corn, 212 F. Supp. 2d at 834.
213. McGarity, supra note 8, at 486; D.L. Uchtmann, StarLink-A Case Study of
Agricultural Biotechnology Regulation, 7 DRAKE J. AGRIC. L. 159, 193-95 (2002).
214. Andrew Pollack,Labeling GeneticallyAltered Food Is Thorny Issue, N.Y. TIMES, Sept.
26, 2000, at Al.
215. Id. The test that discovered the StarLink corn was a test for the genetically modified
DNA, not the potential allergy-causing protein that the DNA might express. The test, thus,
did not establish whether the protein of concern itself was even in the contaminated
products. Id. A test to identify whether processed foods contained the protein of concern did
not exist because the "protein typically is broken down by heating and other food processing."
Feder, supra note 183.
216. See Barnaby J. Feder, Farmers Cite Scarce Data In Corn Mixing: Companies'
Warnings Are Called Inadequate, N.Y. TIMES, Oct. 17, 2000, at Cl; see also In re StarLink
Corn, 212 F. Supp. 2d at 838.
217. George Anthan, OKSought for Corn in Food, DES MOINES REG., Oct. 26,2000, at ID.
The EPA later acknowledged "that the limited approval for StarLink was unworkable." Id.
218. Id.
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B. Genetically Modified Salmon
A genetically modified version of Atlantic salmon is expected to
be the first genetically modified animal approved for sale for human
consumption in the United States.219 These salmon are engineered
to contain genes intended to make them grow faster and use feed
more efficiently.220 The main concern raised by genetically modified
salmon is environmental: Studies have shown that wild fish
populations could be eliminated through mating with genetically
engineered fish.221 In addition, there is the risk of unpredictable
environmental impacts occurring as a result of the introduction of
a nonnative species into an ecosystem.222
In an attempt to limit the potential for wild propagation of
transgenic salmon, the salmon are treated in an effort to produce
only reproductively sterile, all-female offspring.22 1 In addition, the
salmon will be grown in enclosed ocean net pens.22' However, full
sterility currently cannot be achieved and escape of pen fish into
open waters is common. 22' Therefore, escape of fish from pens will
occur and may include females capable of reproduction. As noted
earlier, escaped nontransgenic net pen Atlantic salmon have been
219. Yoon, supra note 168.
220. CASE STUDY No. I: GROWTH-ENHANCED SALMON, supra note 81, at 1.
221. CASE STUDY No. I: GROWTH-ENHANCED SALMON, supra note 81, at 6-7; Yoon, supra
note 168, at Al.
222. CASE STUDY NO. I: GROWTH-ENHANCED SALMON, supra note 81, at 6-7, 24; Yoon,
supra note 168, at Al. Transgenic animals, in particular, "may have surprising ecological
impacts associated with their degree of fitness, interaction with other organisms, role in
ecosystem processes or potential for dispersal and persistence." Id. at 22.
223. CASE STUDY NO. I: GROWTH-ENHANCED SALMON, supra note 81, at 1.
224. Id.
225. Id. at 1-3; CEQAND OSTPASSESSMENT, supra note 49, at 8; FUTURE FISH, supra note
25, at 18; ROYAL SOC'YOF CAN., supra note 5, at 151. It is possible to test the treated fish for
sterility, but testing each salmon would be prohibitively expensive. Id. at 161. To cite one
statistic on net pen escape, between 32,000 and 86,000 farmed salmon escaped in British
Columbia between January and September 2000. Id. at 151.
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known to spawn successfully.226 Only a few fertile individuals are
necessary to change the genetic structure of a wild species.227
Despite these risks, there are no federal laws that directly
regulate the use or release of genetically engineered fish or other
transgenic animals.22 Both the EPA and the USDA have deter-
mined that they do not have regulatory authority over the geneti-
cally modified Atlantic salmon.229 The FDA is the only regulatory
agency to have asserted authority over the transgenic salmon,
which it has done pursuant to the Federal Food, Drug, and
Cosmetic Act (FFDCA),"' on the basis that the transgenic salmon
are a "new animal drug."211 A difficulty with this regulatory basis
is that the salmon have only been modified such that a growth
hormone they naturally produce for half the year is now produced
all year long.2 2 The FDA's authority on this basis, therefore, may
be tenuous.233
226. See supra note 167 and accompanying text. Initially, escape was not anticipated to
be a significant risk for pen-raised Atlantic salmon, because it was believed that escapees
would be few and that any escaped individuals would not be able to compete successfully
with native stocks or form viable populations. Escapees, however, occur in substantial
numbers, and can survive in the wild. Experts still believed that there was not a significant
cause for concern as the salmon were not expected to reproduce successfully in the wild. It
now appears that escaped fish do reproduce. Further, genetically modified salmon may be
able to do so in a broader range of ecosystems than anticipated. CASE STUDYNO. I: GROWTH-
ENHANCED SALMON, supra note 81, at 6-8.
227. CASE STUDY NO. I: GROWTH-ENHANCED SALMON, supra note 81, at 23.
228. Yoon, supra note 168.
229. Id. Some have argued that the EPA could assert regulatory authority over genetically
modified fish by defining the products produced by the tranagenes to be "new chemical
substances" pursuant to the Toxic Substances Control Act (TSCA). FUTURE FISH, supra note
25, at 46. The EPA, however, has not exercised this authority and there is some question
regarding whether such an interpretation would be upheld. Id.
Certain native Atlantic salmon population segments in Maine have been listed as
endangered distinct population segments pursuant to the Endangered Species Act.
Endangered and Threatened Wildlife, 50 C.F.R. § 17.11 (2002); Enumeration of Endangered
Marine and Anadromous Species, 50 C.F.R. § 224.101 (2002). This listing creates certain
protections for these population segments of wild Atlantic salmon, and would likely impact
any discussion of net pen aquaculture of the genetically modified Atlantic salmon in the
vicinity of the listed wild populations. The listing, however, will not impact net pen
aquaculture of genetically modified fish generally, or of modified salmon in other areas.
230. 21 U.S.C. §§ 301-399 (2003).
231. Id. § 321(v); Yoon, supra note 168, at A20.
232. FUTURE FISH, supra note 25, at 6, 8; Yoon, supra note 168, at A20.
233. FUTURE FISH, supra note 25, at 47. The FDA also potentially could rely on the
National Environmental Policy Act (NEPA) as authority to regulate the environmental
impacts of genetically modified fish. See 42 U.S.C. § 4332 (2003).
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The FDA bases its authority on the reasoning that the
FFDCA defines a "drug" to include "articles ... intended to affect
the structure or any function of the body of man or other
animals."234 The genetic modification of the salmon certainly
qualifies as a "drug" under this statutory language, as the modifi-
cation is intended to affect function. On the other hand, the
FFDCA's definition of "new animal drug" refers to substances not
generally recognized as safe (GRAS), and a growth hormone already
present in the salmon likely does not fit this bill.235 The FDA's
reasoning, that the increased protein production is not GRAS, is
particularly questionable considering the FDA's conclusion in the
transgenic crop arena that inserted genetic material is GRAS
because all that is produced as a result of the insertion are proteins
and other substances already commonly found in food.2"" The FDA's
guidance concerning food crops therefore may undermine its
authority over genetically modified fish or other animals. It also is
certain that Congress did not intend "article" to have this expanded
interpretation when the FFDCA was enacted in 1958, since the field
of biotechnology did not exist at that time.
Under the FFDCA, a new animal drug's safety is determined
with "reference to the health of man or animal."237 The FDA inter-
prets this statutory language to include "environmental effects that
directly or indirectly affect the health of humans or animals."3 '
Thus, as a practical matter, many "environmental effects" come
within the FDA's interpreted regulatory jurisdiction under the
FFDCA. Certain environmental effects, however, such as aesthetic
injuries or certain ecological ones, could not be considered by the
Some commentators contend that even if the FDA's authority is improper, genetically
modified fish producers would not challenge the FDA's authority out of fear that a successful
challenge would result in new, potentially more restrictive, legislation and regulation.
FUTURE FISH, supra note 25, at 49. On the other hand, it only takes one allegedly irrational
actor to challenge the FDA's regulatory authority, and predicting congressional response is
a risky enterprise at best.
234. 21 U.S.C. § 321(g).
235. Id. § 321(v).
236. See infra notes 285-88 and accompanying text. The genetic modification in this
instance also may produce a protein that can be considered a drug. This runs into the same
regulatory authority concerns because the protein being produced is one that already occurs
naturally in the salmon.
237. 21 U.S.C. § 321(u).
238. CASE STUDY No. I: GROWTH-ENHANCED SALMON, supra note 81, at 14.
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FDA in determining whether to approve or regulate the salmon.239
In addition, the FFDCA contains no provisions regarding how to
handle environmental risk.
Thus, the best-case scenario, assuming the FDA's interpretation
of "drug" is upheld, is that the FDA is still the only agency with
authority over the introduction of a genetically modified animal
that primarily raises environmental concerns. Even in such a
scenario, the FDA would lack authority over certain environmental
impacts.
C. Threat to Monarch Butterflies
In 1999, a Cornell University study found that pollen from
genetically modified corn containing Bt, a gene from the Bt
bacterium that produces a protein toxic to the European corn
borer,240 was toxic to Monarch butterfly larvae.24' In August 2000,
scientists from Iowa State University published a study showing
that "plants growing in and near the [Btl corn fields are being
dusted with enough toxic pollen to kill [Mlonarch caterpillars that
feed on them."242
At that time, over one-quarter of the seventy-three million acres
of corn planted in the United States was genetically modified to
include the Bt pesticide.243 Approximately half of the Monarchs in
239. FUTURE FISH, supra note 25, at 48-49. The approval of a new animal drug application
is a federal action pursuant to NEPA, thus, the FDA also will have to comply with its
strictures in carrying out the approval process. CASE STUDY No. I: GROWTH-ENHANCED
SALMON, supra note 81, at 14. There are some problems for the FDA complying with NEPA's
public participation requirements during the approval process, because both the FFDCA and
the Trade Secret Act, 18 U.S.C. § 1905 (2002), "prohibit revealing any information that is
acquired as part of the new animal drug approval process." CASE STUDY No. I: GROWTH-
ENHANCED SALMON, supra note 81, at 16; see also FUTURE FISH, supra note 25, at 52.
240. The European corn borer is a significant corn crop pest from the Lepidoptera family
(e.g., moths, butterflies). The European Corn Borer Home Page, at http://www.ent.
iastate.edu/ pest/cornborer (last updated Oct. 28, 1998).
241. John E. Losey et al., Transgenic Pollen Harms Monarch Larvae, 399 NATURE 214
(1999).
242. Carol Kaesuk Yoon, New Data in Duel of Biotech Corn vs. Butterflies, N.Y. TIMES,
Aug. 22, 2000, at F2. According to the Iowa State study, twenty percent of the Monarch
caterpillars eating the leaves bearing the genetically modified pollen died, compared with a
zero fatality rate for caterpillars eating leaves with regular corn pollen. Id.
243. Carol Kaesuk Yoon, Biotech Corn Isn't Serious Threat to Monarchs, Draft U.S. Report
Finds, N.Y. TIMES, Sept. 26, 2000, at F4.
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the United States pass through the corn belt every year. 2 "
Unsurprisingly, the combination of these reports and facts caused
widespread concern among the public and led to cries for bans on
Bt-modified plants.
The EPA had considered the potential impact of Bt-modified
plants on Monarch butterflies prior to approving their registration.
The EPA concluded that Bt crops posed an extremely low risk based
on the expectations that (1) Monarchs did not occur in cornfields
in significant numbers;245 (2) there would be relatively few milk-
weed plants (the Monarch butterfly larvae's sole food source) near
or in the transgenic fields;246 and (3) the amount of Bt pollen that
would land on adjacent milkweed plants would be below toxic
levels.247 The new reports, however, threw the EPA's conclusions
into question.
The EPA responded quickly to the Monarch butterfly concern
by issuing a data call-in, and a variety of field and laboratory data
was collected.24 s Analysis of this data generally "confirmed [the]
EPA's earlier finding that the risk to [adult Mlonarch butterflies
from Bt-maize is extremely low," and also found that Monarch
larvae avoided detrimental amounts of pollen.249 A collaborative
research effort to conduct a formal risk assessment of the impact of
Bt corn on Monarch butterfly populations concluded that the risk
from current crops was low or negligible.25 °
On the other hand, that same risk assessment also found that
Monarch populations inhabit corn ecosystems to a degree previously
undocumented,251 that milkweed plants were abundant throughout
the corn growing region, and that milkweed pollen was shed during
244. CASE STUDY No. II: BT-MAIZE, supra note 36, at 26.
245. NRC 2002 REPORT, supra note 2, at 74.
246. CASE STUDY No. II: BT-MAIZE, supra note 36, at 25.
247. Id.
248. See CASE STUDYNO. II: BT-MAIZE, supra note 36, at 25-26; NRC 2002 REPORT, supra
note 2, at 73-75.
249. CASE STUDYNO. II: BT-MAIZE, supra note 36, at 26; see also NRC 2002 REPORT, supra
note 2, at 37, 75-77.
250. Mark K. Sears et al., Impact of Bt Corn Pollen on Monarch Butterfly Populations: A
Risk Assessment, PNAS vol. 98, No. 21, at 11,937, 11,942 (2001), available at
http://www.pnas.org/cgi/reprint/98/21/11937.pdf (last visited Apr. 7, 2004).
251. Id. at 11,942. Throughout the northern Corn Belt more Monarchs are bred in
cornfields than in any other habitat.
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the same period that larvae develop and use the cornfields.5 2 In
addition, another study found that the "level of natural deposition
of Bt pollen ... was sufficient to kill Monarch larvae."2" The EPA
continues to "assess the potential risks [to Monarchs] and the need
for possible mitigation measures."2 4
The EPA's rapid response to the reports that raised concern is
commendable, and the end result appears to be that Bt crops
present a low risk to Monarch butterfly populations. The assump-
tions that the EPA made in approving the Bt crop registration,
however, were scientifically unsound.
D. ProdiGene Pharmaceutical-Producing Corn
In September 2002, the USDA discovered corn genetically
engineered to produce a pharmaceutical growing in an Iowa
soybean field in violation of regulations. This corn had sprouted
from seed left over from an approved 2001 field test by ProdiGene,
Inc., a pharmaceutical bioengineering company. 25 Because the
corn had already matured, its pollen may have traveled into
nearby fields. The USDA, therefore, ordered the harvest and
destruction of 155 acres of crop surrounding the test site in case
the ProdiGene corn had contaminated it. 25
6
Almost identically, in October 2002, APHIS discovered transgenic
ProdiGene pharmaceutical-producing corn in a Nebraska soybean
field, which also had sprouted from seed left over from a 2001 field
test.257 Apparently, the grower had violated APHIS containment
252. Id. at 11,938-39; NRC 2002 REPORT, supra note 2, at 75.
253. NRC 2002 REPORT, supra note 2, at 74. The levels of natural deposition were found
to be too low to kill adult Monarch butterflies at distances greater than five meters from the
corn field edge. Id.
254. CASE STUDY No. II: BT-MAIZE, supra note 36, at 26.
255. Ann Thayer, Prodi-ene Woes: Biopharm Firm Faces USDA, FDA Actions over Corn
Contamination, CHEM. & ENG'G NEWS, Nov. 25, 2002, available at http://pubs.acs.org/cen/
topstory/8047/8047notw3.html (last visited Apr. 7, 2004).
256. Randy Fabi, USDA Orders ProdiGene Biocorn Destroyed in Iowa, Rueters, Nov. 14,
2002, available at http://www.connectotel.com/gmfood/rel4ll02.txt (last visited Apr. 7,2004);
Press Release, APHIS, USDA Investigates Biotech Company for Possible Permit Violations
(Nov. 13, 2002),available at httpl/www.aphis.usda.gov/lpa/news/2002/ll/prodigene.html (last
visited Apr. 7, 2004).
257. Thayer, supra note 255. Not surprisingly, both the pro-genetically modified product
industry and the anti-genetically modified product activists instantly issued press releases
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requirements by not fully removing the old ProdiGene corn plants
from the field.258 About 500 bushels of soybeans had been harvested
from the field, which had then been mixed with 500,000 bushels of
soybeans in a grain elevator.259 APHIS impounded and destroyed
the 500,000 bushels of soybeans, worth an estimated $2.7 million.
The ProdiGene corn had been modified to produce an experimental
vaccine for use against viral disease in pigs.
261
Following the two incidents, ProdiGene and the USDA entered
a consent decision and order regarding violations of the Plant
Protection Act (PPA).26 2 ProdiGene agreed to pay a $250,000 civil
fine and to reimburse the USDA approximately $3 million for the
costs of acquiring and destroying the 500,000 bushels of soybeans
in Nebraska.26 3 ProdiGene did not admit or deny any violations of
the PPA.2
64
Shortly after the ProdiGene incidents, the EPA levied fines
against two other firms (Dow Agrosciences and Pioneer Hi-Bred) for
contending, respectively, that this incident either demonstrated that the current regulatory
system was functioning well, or that the biotechnology industry cannot be trusted. Compare
Press Release, Biotechnology Industry Organization, Bio Statement on ProdiGene, Inc. (Nov.
15, 2002), available at http://www.bio.org/newsroom/newsitem.asp?id=2002_1115-01 (last
visited Apr. 7, 2004) ("The ProdiGene incident demonstrates that the regulatory framework
governing plant-made pharmaceutical crops works."), with Press Release, Friends of the
Earth, Coalition to File Legal Petition Demanding Immediate Halt of Experimental
Biopharmaceuticals Grown on Farms (Nov. 14, 2002), at http://www.foe.org/new/releases/
1102biopharml.html (last visited Apr. 7, 2004) ("With this latest contamination the
government should halt all experimental genetically engineered crops grown on farms .... ")
(internal citation omitted).
258. See APHIS, supra note 256.
259. See Philip Brasher, Biotech Corn May Have Tainted Soybeans, DES MOINES REG.,
Nov. 13, 2002, at Al.
260. Andrew Pollack, US. Investigating Biotech Contamination Case, N.Y. TIMES, Nov.
13, 2002, at C7; APHIS, supra note 256; Press Release, USDA, USDA Announces Actions
Regarding Plant Protection Act Violations Involving ProdiGene, Inc. (Dec. 6,2002), available
at http://www.usda.gov/news/releases/2002/12/0498.htm (last visited Apr. 7, 2004).
261. TAYLOR & TICK, supra note 20, at 88.
262. USDA, supra note 260.
263. See id.; see also TAYLOR & TICK, supra note 20, at 89. "ProdiGene also agreed to a $1
million bond and higher compliance standards, including additional approvals before field
testing and harvesting genetically modified material," and to "develop a written compliance
program with USDA to ensure that its employees, agents, cooperators and managers are
aware of, and comply with, the [PPA], federal regulations and permit conditions." USDA,
supra note 260.
264. TAYLOR & TICK, supra note 20, at 89.
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failing to take proper measures to protect against experimental
pharmaceutical-producing plants contaminating other crops.
265
To guard against future incidents and to allay consumer and food
industry concerns, the Biotechnology Industry Organization (BIO),
a biotechnology trade organization, initially directed its members
not to plant pharmaceutical-producing plants in the Midwest and
Plains states. 6 This policy caused widespread concern among
farmers in the corn belt who desired to plant these potentially
highly profitable crops. 6 ' BIO later reversed its position because of
political pressure from these farmers.68
Perhaps in response to the incidents identified above, the
USDA recently proposed new guidelines for the field testing of
pharmaceutical-producing and industrial compound-producing
genetically modified plants. Among other changes, these proposed
regulations would increase the number of field site inspections
made by APHIS during the growing season.26 9
These brief case studies simultaneously demonstrate the need to
properly regulate genetically modified products and also provide
valuable insight into the regulatory deficiencies that currently
exist with respect to genetically modified products. To understand
why these problems are occurring, to identify additional issues, and
to provide background for improving the regulatory structure
governing genetically modified products, the current statutory and
regulatory structure governing genetically modified plants and
animals is outlined in the following section.
265. Justin Gillis, EPA Fines Biotechs for Corn Violations, WASH. POST, Dec. 13, 2002, at
E3.
266. TAYLOR & TICK, supra note 20, at 89.
267. Id.
268. Sandra Guy, Kraft Exec Wants Tougher Rules on Planting Crops for Drugs, CHI. SUN-
TIMES, Apr. 4, 2003, at 50.
269. Field Testing of Pharmaceutical Plants, supra note 23, at 11,338.
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IV. CURRENT REGULATION OF GENETICALLY MODIFIED PLANTS AND
ANIMALS
A. The Coordinated Framework
As the biotechnology industry developed in the early 1980s,
it was recognized that regulation was necessary to protect human
health and the environment from the potential deleterious
effects of transgenic products. This recognition culminated in the
promulgation of the federal government's Coordinated Framework
for Regulation of Biotechnology by the White House Office of
Science and Technology Policy in 1986.27' The Coordinated
Framework instituted a "comprehensive federal regulatory policy
for ... biotechnology research and products."27' It specified that
bioengineered products generally would be regulated under the
then-existing statutory and regulatory structure.272 The foundation
for this decision was a determination that the process of biotechnol-
ogy was not inherently risky, and therefore, that only the products
of biotechnology, not the process itself, required oversight. On this
basis, the Coordinated Framework established that existing laws
and regulations were sufficient to handle the products of biotechnol-
ogy.273 This decision was based in part on a desire not to impose
regulatory restrictions that could hamper the development of a
promising and fledgling industry.27'
As a result of the Coordinated Framework, three administrative
agencies are involved in the regulation of the genetically modified
products discussed in this Article: The FDA is responsible for food
safety issues for transgenic crop and food-animal varieties, and for
drug safety issues for modified pharmaceutical-producing plants or
animals; the EPA handles health and environmental effects of pest-
protected plants; and the USDA regulates the effect of genetically
modified plants on other plants and animals in both agricultural
270. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302 (June
26, 1986).
271. Id. at 23,302.
272. Id. at 23,302-08, 23,309, 23,313-14, 23,336.
273. Id. at 23,302-03; see NRC 2000 REPORT, supra note 4, at 25-26.
274. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. at 23,302-03.
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and nonagricultural environments.2 7' Because the Coordinated
Framework would result in multiple agencies acting in closely
related areas, two basic principles were delineated to guide
regulatory policy. First, "[a]gencies should seek to adopt consistent
definitions of those genetically engineered organisms subject to
review to the extent permitted by their respective statutory
authorities."27 Second, the "agencies should utilize scientific
reviews of comparable rigor."2
77
Implicit in the decision to regulate genetically modified products
under preexisting statutes was the belief that bioengineered plants
and animals were not significantly different from their conventional
counterparts. This view was explicitly reiterated in a 1987 National
Academy of Sciences report that reached three conclusions:
[1] There is no evidence that unique hazards exist either in
the use of rDNA techniques or in the movement of genes
between unrelated organisms.
[21 The risks associated with the introduction of rDNA-
engineered organisms are the same in kind as those
associated with the introduction of unmodified organisms
and organisms modified by other methods.
[31 Assessment of the risks of introducing rDNA-engineered
organisms into the environment should be based on the
nature of the organism and the environment into which
it is introduced, not on the method by which it was pro-
duced.278
With the Coordinated Framework in place, the regulation of
biotechnology was left to the administrative agencies.
275. NRC 2002 REPORT, supra note 2, at 19.
276. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. at 23,303.
277. Id.
278. NAT'L ACAD. OF SCIENCES, INTRODUCTION OF RECOMBINANT DNA-ENGINEERED
ORGANISMS INTO THE ENVIRONMENT: KEY ISSUES (1987). This position was confirmed again
in 1992 by the Office of Science and Technology Policy. Exercise of Federal Oversight Within
Scope of Statutory Authority: Planned Introductions of Biotechnology Into the Environment,
57 Fed. Reg. 6753 (Feb. 27, 1992).
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B. The Food and Drug Administration
The FDA is responsible for insuring that all food products on the
market in the United States, other than meat and poultry, are safe.
In furtherance of this goal, the FDA provides voluntary premarket
consultations with food companies, seed companies, and plant
developers regarding the safety of transgenic foods.
The FDA's statutory authority is the FFDCA, enacted in 1938.279
No statutory provisions or FDA regulations expressly cover
genetically modified foods. Pursuant to FDA regulations, plants
modified through modern rDNA techniques are not treated any
differently from conventionally modified plants.8 °
Section 402(a)(1) of the FFDCA authorizes the FDA to regulate
"adulterated foods," defined as food that "bears or contains any
poisonous or deleterious substance which may render it injurious
to health."28' In addition, section 409 of the FFDCA provides for
the regulation of "food additives," which are substances that are
intended for use in food, that may reasonably be expected to become
a component of food, or that otherwise may affect the characteris-
tics of food.282 A food additive must be approved by the FDA prior to
being used in food.2"' Manufacturers, however, do not need approval
for a food additive if such substance is generally recognized as safe
(GRAS) by experts.28'
Thus, both the inserted gene of a transgenic plant and the
product that it expresses are food additives, unless they are
GRAS.285 With respect to genetically modified foods, the FDA has
determined that "[iin most cases, the substances expected to become
components of food as a result of genetic modification of a plant will
be the same as or substantially similar to substances commonly
279. See 21 U.S.C. §§ 301-399 (2003).
280. Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed. Reg. 22,984
(May 29, 1992).
281. 21 U.S.C. § 342(a)(1). "Food" is defined as (1) articles used for food or drink for man
or other animals, (2) chewing gum, and (3) articles used for components of any such article."
Id. § 321(f). This includes human food, animal food, pet food, and substances migrating to
food from food-contact articles. Definitions, 21 C.F.R. § 170.3(m) (2003).
282. 21 U.S.C. §§ 321(s), 348.
283. Id. § 348.
284. Id. § 321(s).
285. Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed. Reg. at 22,990.
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found in food, such as proteins, fats and oils, and carbohydrates,"
and therefore will be GRAS.286
The food additive manufacturer determines whether a food
additive is GRAS, not the FDA. 7 A manufacturer does not need to
report to the FDA that it has made a GRAS determination, but
it may do so and may receive from the FDA an affirmation that
the particular substance is GRAS.288 Thus, the FDA's regulatory
requirements with respect to genetically modified food are primar-
ily voluntary. This decision was explicitly made by the FDA based
on its determination that "[a]ny genetic modification technique has
the potential to alter the composition of food in a manner relevant
to food safety, although, based on experience, the likelihood of a
safety hazard is typically very low."2"9
In 1995, the FDA conducted a safety review of the first geneti-
cally modified food product to be commercialized, the Flavr Savr
tomato.290 This review was conducted at the request of the manufac-
turer, who was attempting to build public confidence.291 Since that
time, the FDA has not conducted a safety review of any of the scores
of other genetically modified food products that have been commer-
cialized; however, the FDA believes that manufacturers have
voluntarily consulted with it regarding each of these products.292
286. Id. at 22,985. The primary exceptions, where foods would require special review,
would be where the gene transfer produces unexpected genetic results, may cause allergic
reactions, significantly increases the level of toxicants, or changes the nutrient composition
of the food. Id. at 22,993 fig.1.
287. Id. at 22,989.
288. Affirmation of Generally Recognized As Safe (GRAS) Status, 21 C.F.R. § 170.35
(2003). Such a determination will protect the product from enforcement actions. Id.
289. Statement of Policy: Foods Derived from New Plant Varities, 57 Fed. Reg. at 22,986.
A challenge to the FDA's decision not to regulate genetically modified food differently from
conventional food was dismissed. Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166
(D.D.C. 2000).
On January 18, 2001, the FDA published proposed revised regulations for genetically
engineered food. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706 (Jan.
18, 2001) (to be codified at 21 C.F.R. pts. 192, 592). These regulations would require
manufacturers and importers to provide the FDA with premarket notification of their intent
to market genetically modified foods that have not been subject to a previous premarket
notification. Id. at 4707. These proposals, made days before President George W. Bush took
office, have not been finalized or acted upon since that time.
290. Henkel, supra note 3.
291. Id.
292. Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. at 4708; NRC 2000
REPORT, supra note 4, at 29; Press Release, FDA, FDA To Strengthen Premarket Review of
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The FDA does not require that genetically modified foods be
labeled as such. The basis for this determination is the FDA's
conclusion that genetically modified products do not differ materi-
ally from, or create greater safety concerns than, their conventional
counterparts.293 To the extent that there are significant safety
concerns or usage issues, such as substantial changes in composi-
tion or nutritive value, the FDA requires labeling.294
The FDA explicitly has waived its regulatory authority over
genetically modified pest-protected plants, so long as the plants
have not also been modified to express other, nonpesticidal
proteins.295 These plants are regulated by the EPA as pesticides,
and are discussed below.296
As discussed in the genetically modified salmon case study, the
FDA asserts regulatory authority over genetically modified fish
and other animals pursuant to the "new animal drug" provisions
of the FFDCA.297 These provisions allow the FDA to evaluate the
new animal drug's safety with "reference to the health of man or
Bioengineered Foods (May 3, 2000), available at httpJ/www.fda.gov/bbs/topica/NEWS/
NEW00726.html (last visited Apr. 7, 2004). The FDA has been consulted on more than fifty
bioengineered plants. BIOENGINEERED FOODS LIST, supra note 15. The FDA has not required
any of the transgenic plants, or their expression products, to be reviewed as food additives.
NRC 2000 REPORT, supra note 4, at 29.
293. Statement of Policy: Foods Derived from New Plant Varities, 57 Fed. Reg. at 22,991.
294. Id. In Alliance for Bio-Integrity v. Shalala, the court upheld the FDA's decision not
to require labeling based on consumer interest. Alliance for Bio-Integrity, 116 F. Supp. 2d at
181. Proponents of genetically modified food labeling point out an apparent inconsistency in
FDA regulations, as the FDA does require labeling based on processing differences and
consumer interest in certain other areas. Examples include labeling requirements for juice
made from concentrate and for food that has been frozen. See Beverages that Contain Fruit
or Vegetable Juice, 21 C.F.R. § 102.33 (2003) (labeling requirements for juice from
concentrate); False or Misleading Labeling on Containers, 9 C.F.R. § 381.129 (2003) (labeling
requirements for previously frozen poultry).
295. Statement ofPolicy: Foods Derived from New Plant Varieties, 57 Fed. Reg. at 23,005.
296. See infra Part IV.C; see also Exemption from the Requirement of a Tolerance Under
the Federal Food, Drug, and Cosmetic Act for Residues Derived Through Conventional
Breeding from Sexually Compatible Plants of Plant-Incorporated Protectants (Formerly
Plant-Pesticides), 66 Fed. Reg. 37,830, 37,835 (July 19, 2001) (to be codified at 40 C.F.R. pt.
174) [hereinafter Exemption for Residues Derived Through Conventional Breeding];
Regulations Under the Federal Insecticide, Fungicide, and Rodenticide Act for Plant-
Incorporated Protectants (Formerly Plant-Pesticides), 66 Fed. Reg. 37,772, 37,775 (July 19,
2001) (to be codified at 40 C.F.R. pts. 152, 174) [hereinafter Regulations Under FIFRA (EPA
regulations for pest-protected plants).
297. See supra notes 230-39 and accompanying text.
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animal,"298 which the FDA interprets to include environmental
effects that directly or indirectly affect the health of humans or
animals other than those intended to receive the new drug.29
The FDA has regulatory authority over pharmaceuticals grown
in genetically modified plants that are intended for use in
humans pursuant to the Public Health Service Act 0 and the
FFDCA. A full discussion of FDA regulations governing the
approval of pharmaceuticals for human use is beyond the scope of
this Article. It is sufficient to note that FDA regulations are similar
to those governing transgenic plants used for food. In both cases,
the FDA regulates the use of plants that might express an
allergenic or toxic compound in the pharmaceutical, and protects
against the introduction of nonfood material into food or feed. 30' The
FDA regulations governing human drugs and biologics and animal
drugs do not specifically address biotechnology.302 The USDA shares
regulatory authority over the growth of the genetically engineered
pharmaceutical-producing plants, as discussed below.03
C. The Environmental Protection Agency
The EPA regulates genetically modified products through its
authority to regulate pesticide use and pesticide residue in food
products. All pesticides must be registered with the EPA prior to
their distribution, sale, or use, pursuant to the Federal Insecticide,
Fungicide, and Rodenticide Act (FIFRA), originally enacted in
1947.304 "Pesticide" is defined under FIFRA to include any sub-
298. 21 U.S.C. § 321(u) (2000).
299. CASE STUDY No. I: GROWTH-ENHANCED SALMON, supra note 81, at 14.
300. 42 U.S.C. § 262-262a (2003).
301. See FDA, GUIDANCE FOR INDUSTRY: DRUGS, BIOLOGICS, AND MEDICAL DEVICES
DERIVED FROM BIOENGINEERED PLANTS FOR USE IN HUMANS AND ANIMALS (DRAFt GUIDANCE)
(Sept. 2002), available at http://www.fda.gov/cber/gdlns/bioplant.pdf (last visited Apr. 7,
2004).
302. ANIMAL BIOTECHNOLOGY, supra note 27, at 164.
303. See infra Part IV.D.
304. 7 U.S.C. § 136-36a (2000). The EPAhas the authority teregulate chemical substances
under the TSCA, 15 U.S.C. §§ 2601-2629 (2000), but has determined that transgenic plants
are not chemical substances. Statement of Policy, Microbial Products Subject to the Federal
Insecticide, Fungicide, and Rodenticide Act and the Toxic Substances Control Act, 51 Fed.
Reg. 23,313,23,324 (June 26, 1986). The EPA regulates genetically modified microorganisms
pursuant to TSCA, defining microorganisms as chemical substances. Coverage of this Part,
40 C.F.R. § 725.8(c)(1) (2001).
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stance "intended for preventing, destroying, repelling, or mitigating
any pest."30 5 To register a pesticide, one must demonstrate that the
pesticide will not cause "unreasonable adverse risk to man or to the
environment." °6 The EPA has authority to exempt pesticides from
registration requirements if it determines them "to be of a character
which is unnecessary to be subject to [FIFRA] in order to carry out
the purposes of [FIFRA] .'°7
FIFRA was enacted to regulate chemical substances, not
biotechnological products (it was enacted prior to Watson and
Crick's discovery of the DNA molecule). Based on FIFRA's statu-
tory definition of "pesticide," however, the EPA regulates the
genetic material inserted into transgenic plants to express pestici-
dal products, as well as the expression products themselves, as
pesticides."' Thus, manufacturers of transgenic pest-protected
plants must receive registration of the plants from the EPA prior to
commercialization. Certain congressional members and professional
societies have contended that the EPA does not have authority to
regulate transgenic pest-protected plants as pesticides under
FIFRA, but the regulations have not been challenged in court.0 9
In 1988, just prior to the widespread development of genetically
engineered pest-protected plants, the EPA exempted plants and
305. 7 U.S.C. § 136(u).
306. Id. § 136a(c)(8).
307. Id. § 136w(b). The EPA will exempt pesticides where there is "a low probability of risk
to the environment, and lit] is not likely to cause unreasonable adverse effects [on] the
environment even in the absence of regulatory oversight under FIFRA.' Regulations Under
FIFRA, supra note 296, 66 Fed. Reg. at 37,773. The EPA has exempted pest-protected plants
that are derived through conventional breeding processes from pesticide registration
requirements. Exemption for Residues Derived Through Conventional Breeding, supra note
296, 66 Fed. Reg. at 37,835. The EPA also has used this exemption process to exempt from
the FFDCA tolerance requirements "residues of nucleic acids that are part of a plant-
incorporated protectant." Exemption from the Requirement for a Tolerance Under the
Federal Food, Drug, and Cosmetic Act for Residues of Nucleic Acids That are Part of Plant-
Incorporated Protectants (Formerly Plant-Pesticides), 66 Fed. Reg. 37,817, 37,820 (July 19,
2001).
308. Regulations Under FIFRA, supra note 296, 66 Fed. Reg. at 37,772-73.
309. NRC 2000 REPORT, supra note 4, at 38. In addition, they have raised concerns that
the EPA regulation lacks "formal cost-benefit analysis," that it "could damage the
[technological] progress ... by overburdening small biotechnology companies and public
breeding programs," and could undermine "[public] confidence in the food supply." Id.
Regarding the first issue, the lack of formal cost-benefit analysis, it is worth noting that the
registration decision takes into account the "economic, social, and environmental costs and
benefits" of the pesticide. 7 U.S.C. § 136(bb).
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microorganisms with pesticidal properties from the requirements
of FIFRA.s1 ° This exemption was intended for plants, such as
chrysanthemums, that are naturally pest-protected.3 1 ' Due to these
regulations, the EPA does not regulate any plants themselves,
including genetically modified ones. 12 As discussed above, the EPA
does regulate the inserted genetic material and the products it
expresses.
The EPA is responsible for regulating both the environmental
and human health impacts of plants genetically modified to produce
their own pesticides, as the FDA has ceded regulatory authority
over pest-protected plants to the EPA. 13 Where use of a pesticide
will result in any residue being left on food, the pesticide is subject
to regulation by the EPA pursuant to the FFDCA. In these in-
stances, the EPA establishes "tolerance" levels for the allowable
amount of pesticide residue that can be left on food products.3 1
4
Currently, all FIFRA-registered, pest-protected plants are exempt
from tolerance level requirements because tests of these transgenic
plants have not revealed a human health risk. 15
The EPA does not regulate genetically engineered plants other
than those modified to contain pesticides,31 6 and it does not regulate
the environmental impacts or potential impacts of genetically
engineered animals.
D. The U.S. Department of Agriculture
The USDA is responsible for protecting and promoting American
agriculture. On the principle that genetically modified plants could
pose a risk to agricultural crops, the USDA oversees the agricul-
310. Exemptions for Pesticides Regulated by Another Federal Agency, 40 C.F.R. § 152.20
(2001); see Pesticide Registration Procedures, Pesticide Data Requirements, 53 Fed. Reg.
15,952, 15,975 (May 4, 1988) (to be codified at 40 C.F.R. pts. 152-53, 156, 158, 162).
311. NRC 2000 REPORT, supra note 4, at 150.
312. See 40 C.F.R. § 152.20a (2001); Regulations Under FIFRA, supra note 296, 66 Fed.
Reg. at 37,774.
313. See 7 U.S.C. § 136(bb). The registration process requires submission of information
on the potential beneficial or adverse effects of the pesticide on human health and the
environment. Id. § 136a(cX2).
314. 21 U.S.C. § 346a (2000).
315. See Exemption from the Requirement of a Tolerance, 40 C.F.R. § 180.1155 (2001).
316. For example, it does not regulate herbicide-resistant or disease-resistant plants.
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tural safety of the movement, importation, and field testing of
transgenic plants.
In order to grow transgenic plants outside of a laboratory,
approval must be obtained from the Animal and Plant Health
Inspection Service (APHIS) of the USDA. APHIS' authority to
regulate genetically modified plants stems from the Plant
Protection Act (PPA).s17 The PPA was enacted in 2000, and thus, at
first glance, appears to deviate from the trend of regulating
biotechnology under ancient statutes. The PPA, however, essen-
tially consolidated authority from two previous statutes that APHIS
had used to regulate genetically modified organisms: the Federal
Plant Pest Act (FPPA), is enacted in 1957, and the Federal Plant
Quarantine Act (PQA),s19 enacted in 1912. Both the FPPA and
PQA were originally enacted to regulate the introduction of
nonindigenous plant species. 2 ' APHIS regulations governing
genetically modified plants under the PPA are simply those
established pursuant to the FPPA and the PQA.3 21 No modification
to APHIS' regulation of biotechnology products has been made
pursuant to the PPA.3 22
Pursuant to the PPA, APHIS has primary regulatory authority
for all genetically modified plants except pest-protected ones. 23 As
APHIS is supposed to carry out its mandate while not impeding
the growth of the biotechnology industry, 2' critics have contended
that an agency charged with promoting agriculture (including the
317. 7 U.S.C. §§ 7701-7772 (2003).
318. 7 U.S.C. §§ 150aa-150jj (1994).
319. Id. §§ 151-164, 166-167.
320. See Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302,
23,342-43 (June 26, 1986).
321. See Plant Protection Act, Revisions to Authority Citations, 66 Fed. Reg. 21,049 (Apr.
27, 2001) (revising the genetically modified plant regulations to change authority citations
to the PPA without substantively changing the regulations); TAYLOR & TICK, supra note 20,
at 25. The PPA was enacted as part of the Agricultural Risk Protection Act of2000, pursuant
to H.R. 2559. There was no Senate or House debate on the PPA portions of H.R. 2559, and
there is little legislative history to indicate what Congress' intent was with respect to
genetically modified plants when it passed the PPA.
322. Where APHIS has promulgated new regulations subsequent to the enactment of the
PPA, such regulations have not differed "from what [APHIS] would have proposed under the
authority of th[e] applicable provisions of law that were repealed by the Plant Protection
Act." Plant Pest Regulations, Update of Current Provisions, 66 Fed. Reg. 51,340 (Oct. 9,
2001); see TAYLOR & TICK, supra note 20, at 25.
323. NRC 2002 REPORT, supra note 2, at 101.
324. Id. at 49.
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biotechnology industry), "may not be able to objectively assess the
safety of new products of agricultural biotechnology."
32
Under the PPA, anyone seeking to introduce (i.e., import,
transport interstate, or release into the environment) 32 a regulated
article must receive authorization from APHIS. 27 "Regulated
article" includes
[any organism which has been altered or produced through
genetic engineering, if the donor organism, recipient organism,
or vector or vector agent belongs to any genera or taxa desig-
nated in § 340.2 [a list of known plant pests] and meets the
definition of plant pest, or is an unclassified organism and/or an
organism whose classification is unknown, or any product which
contains such an organism, or any other organism or product
altered or produced through genetic engineering which [APHISI
determines is a plant pest....
A "plant pest" includes a wide variety of organisms "which can
directly or indirectly injure or cause disease or damage in or to any
plants or parts thereof."3 29 This definition is very broad-any
species that interacts ecologically with a plant likely could be
considered to indirectly injure or damage it. 33°
Prior to conducting a field trial of a new transgenic plant, a
developer must perform a risk evaluation on the plant to determine
whether the plant may be a plant pest. No consideration of any
other risks, such as other human health or environmental risks,
must be evaluated prior to the field test.3 1
Authorization from APHIS can come via a notification or
permitting process, each of which is aimed at ensuring that the
325. Id. at 19.
326. "Environmental release" is the use of a regulated article outside the physical
constraints of a laboratory, contained greenhouse, or other contained structure. Definitions,
7 C.F.R. § 340.1 (2003).
327. Restrictions on the Introduction of Regulated Articles, 7 C.F.R. § 340.0 (2003).
328. 7 C.F.R. § 340.1. Note that this defiition is explicitly based on the organism's having
been developed through genetic engineering; i.e., it regulates based on the process by which
the article was produced, not based on the product. One result of the taxonomic list
restriction is that vertebrates cannot be considered plant pests. Groups of Organisms Which
Are or Contain Plant Pests, 7 C.F.R. § 340.2 (2003).
329. 7 C.F.R. § 340.1.
330. Id.
331. 7 C.F.R. § 340.0.
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transgenic organisms are grown and handled in a manner to
prevent their escape into the environment. For most genetically
modified plants, under certain conditions, simple notification of
APHIS prior to release (without the requirement of receiving a
permit) is sufficient.332 Nearly 99% of all field tests, importations,
and interstate movement of genetically engineered plants take
place under the notification system.333
Permits are required for the movement, importation, and field
testing of transgenic plants that do not qualify for notification, such
as pharmaceutical-producing plants, and for plants denied notifica-
tion.334 APHIS uses the permitting process to evaluate potential
plant pest risk and to require prevention measures to reduce risk.3 5
The primary emphasis of the permitting process is confinement.
38
An applicant can petition APHIS to determine that a certain
genetically modified plant is not a plant pest (essentially that the
regulated article is free from the risks outlined above), and
therefore should be given "nonregulated status."33 7 Plants granted
nonregulated status, as well as their progeny, are no longer subject
to any APHIS oversight-they may be freely planted, transported,
and sold. 3 8 This process is the sole manner in which transgenic
plants can be commercialized, and the primary, though not sole,
route through which the products of transgenic plants can be
332. Notification for the Introduction of Certain Regulated Articles, 7 C.F.R. § 340.3
(2003). The notification process applies to a specified list of plants and characteristics.
Requirements include: confinement; that the plant not be listed as a noxious weed or
considered a weed in the area of release; that the inserted gene be stably integrated; that the
function of the inserted gene be known; that the inserted gene's expression not result in
plant disease; that the inserted gene be derived from human or animal viral pathogens; and
that the inserted gene does not cause the production of an infectious entity, encode for
substances likely to be toxic to nontarget species or to feed on the plant, or encode for
products intended for pharmaceutical use. NRC 2002 REPORT, supra note 2, at 108-09.
The applicant must notify APHIS of its intent to release a regulated article. APHIS staff
reviews the notification for qualification and completeness, and then sends a
recommendation to state officials for concurrence. The entire process must be completed in
ten days for interstate movement, and thirty days otherwise. 7 C.F.R. § 340.3.
333. CAsE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN, supra note 73, at 4.
334. NRC 2002 REPORT, supra note 2, at 110.
335. Id.
336. Id.
337. Petition for Determination of Nonregulated Status, 7 C.F.R. § 340.6 (2003).
338. Id. Prior to receiving nonregulated status, APHIS must conduct an Environmental
Assessment pursuant to NEPA. 42 U.S.C. § 4332 (2000); 40 C.F.R. §§ 1500-1508 (2003).
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commercialized (e.g., sale of an industrial protein derived from a
plant).339
APHIS regulates transgenic pharmaceutical-producing plants
pursuant to the same authority under which it regulates other
transgenic plants, such as "regulated articles" under the PPA.34°
Thus, applicants must acquire a permit prior to the field test of
transgenic pharmaceutical-producing plants, as such plants are
specifically excluded from the notification process.3 4 ' Various
measures must then be taken to confine the transgenic plants to the
field site during the period of release, and to prevent the plants or
their offspring from persisting in the environment subsequently. 42
With respect to biotechnology developments beyond plants, the
Food Safety and Inspection Service (FSIS) of the USDA is respon-
sible for the safety of food products prepared from domestic
livestock and poultry. 43 The Federal Meat Inspection Act (FMIA)
and the Poultry Products Inspection Act (PPIA) require FSIS to
inspect cattle, sheep, swine, goats, equines, poultry, and food
products prepared from them, which are intended for use as human
food.3 4 Pursuant to these acts, the FSIS has regulatory authority
over genetically modified domestic livestock and poultry.
339. NRC 2002 REPORT, supra note 2, at 111. [C]ormmercial products have also been
created from regulated transgenic [plants]." Id. at 120. APHIS has deregulated many
genetically modified crops. For a list of the deregulated plants, as well as pending
deregulation petitions, see APHIS, PETITIONS OF NONREGUIATED STATUS GRANTED OR
PENDING (last updated Mar. 30, 2004), at http://www.aphis.usda.gov/brs/not.reg.html (last
visited Apr. 12, 2004).
340. Restrictions on the Introduction of Regulated Articles, 7 C.F.R. § 340.0 (2003)
341. Permits for the Introduction of a Regulated Article, 7 C.F.R. § 340.4 (2003).
342. Notification for the Introduction of Certain Regulated Articles, 7 C.F.R. § 340.3
(2003). Earlier regulations required that the pharmaceutical-producing plants be isolated by
a 1320-foot buffer from other plants in order to prevent cross-pollination, a distance twice
that used to assure purity of their seeds. Minimum Land, Isolation, Field, and Seed
Standards, 7 C.F.R. § 201.76 (2003); Pollack, supra note 22, at Al. Regulations proposed by
APHIS would increase the buffer zone to one-half to one mile depending on certain factors.
Field Testing of Pharmaceutical Plants, supra note 23, 68 Fed. Reg. at 11,338.
Other protective techniques are being developed. These include implanting a gene to turn
the pharmaceutical-producing plant a different color and harvesting the pharmaceutical-
producing plants before sexual maturity. Pollack, supra note 22, at Al.
343. See 21 U.S.C. §§ 451,601,1031 (2003) (granting the FSIS administrator the authority
to regulate the safety of domestic livestock, poultry, and poultry products); Purpose, 9 C.F.R.
§ 300.1 (2003); FSIS Responsibilities, 9 C.F.R. § 300.2 (2003); FSIS Organization, 9 C.F.R.
§ 300.3 (2003) (establishing the FSIS within the USDA).
344. 21 U.S.C. §§ 451, 601, 1031.
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APHIS also has regulatory authority over the release of insects
for pest management,3 45 and presumably would regulate the release
of transgenic insects in the same manner. No agency regulates
research and commercialization of transgenic insects other than
for their intentional release, and no guidelines exist that govern
their containment or the potential ecological risks posed by their
release.346
As evidenced by the preceding analysis, the statutory structure
under which biotechnological products are regulated in the United
States is based on legislation enacted decades ago, long before
transgenic products were scientifically conceivable. As a result of
dated statutes, and decisions made in the Coordinated Framework
and thereafter, the regulations governing genetically modified
products have been developed in a piecemeal, haphazard manner.
Genetically modified plants and animals are now governed by as
many as twelve different statutes and five different agencies or
services.347
345. 7 U.S.C. § 7701 (2003); Authority ofthe Secretary to Delegate Authority, 7 C.F.R. §
2.3 (2003); Under Secretary for Marketing and Regulatory Programs, 7 C.F.R. § 2.22 (2003);
Administrator, Animal and Plant Health Inspection Service, 7 C.F.R. § 2.80(aX51) (2003).
346. ANiMAL BIOTECHNOLOGY, supra note 27, at 21, 88-89, 114. For a discussion of how
certain existing statutes could be applied to transgenic insects, see BUGS IN THE SYSTEM,
supra note 91.
347. See Table 1, infra.
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Table 1




Food and food additives FFDCA FDA
Meat, poultry, egg products FMIA 3 49 PPIA,350 FSIS
Pesticide residues EPIAA EPA
FFDCA
Production of pharmaceuticals
Human drugs FFDCA FDA
Human biologics PHS Act,352 FFDCA FDA
Animal drugs FFDCA FDA
Animal biologics AQL,3 5 3 VSTA 54  APHIS
Production of pesticidal FIFRA EPA
substances in plants PPA APHIS
Production of plant herbicide- PPA APHIS
tolerance FIFRA EPA
Herbicide usage on plants
Biocontrol of plants PPA APHIS
FIFRA EPA
Biocontrol of plant pests PPA APHIS
FIFRA EPA
Biomedical research on AWA3 55  APHIS
animals HREA
356  NIH357
348. ANIMAL BIOTECHNOLOGY, supra note 27, at 162-64; CEQ AND OSTP ASSESSMENT,
supra note 49, at 6. This Table lists the common uses of genetically modified plant and
animal products, the statutes under which they are regulated, and the regulating agency
under each statute. A careful reader will note that this Table lists only eleven statutes. As
discussed elsewhere in this Article, the Animal Health Protection Act (AHPA) (enacted in
2002) may represent the twelfth statutory authority concerning genetically modified plants
and animals. See infra note 371.
349. Federal Meat Inspection Act, 21 U.S.C. §§ 601-691 (2003).
350. Poultry Products Inspection Act, 21 U.S.C. §§ 451-471 (2003).
351. Egg Products Inspection Act, 21 U.S.C. §§ 1031-1056 (2003).
352. Public Health Service Act, 42 U.S.C. §§ 262, 264 (2003).
353. Animal Quarantine Laws, 21 U.S.C. §§ 101-135 (2003).
354. Virus, Serums, and Toxins Act, 21 U.S.C. §§ 151-159 (2003).
355. Animal Welfare Act, 7 U.S.C. §§ 2131-2159 (2003).
356. Health Research Extension Act, 42 U.S.C. §§ 201-300gg-92 (2003).
357. National Institutes of Health.
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The multiplicity of statutes and agencies regulating biotechnol-
ogy has created confusion among the regulated industries and the
public, reduced clarity regarding scientific standards and require-
ments, and retarded the efficiency of biotechnology development
and regulation. Not surprisingly, this fractured approach to
regulation has led to numerous problems. Some of these problems
were made evident in the case studies, some are evident from the
preceding analysis of agency authority, and others are revealed
through additional investigation. These regulatory problems are
discussed and categorized in the following section.
V. REGULATORY GAPS, INCONSISTENCIES, INEXPERIENCE, AND
OVERLAPS
The statutory and regulatory regime for genetically modified
products described in the preceding section only partially reveals
how these products are actually regulated in practice. In practice,
the quality of transgenic product regulation is affected by issues of
agency financial and personnel resources, agency priorities,
agency decision-making structures, the quality of and reliance on
in-house and third-party research, agency capture, political
pressure, and other factors. The case studies discussed in Part III
provide insight into the actual application of genetically modified
product regulation. The following section provides examples of
additional regulatory issues that have arisen, and weaves this
analysis into a framework for understanding the types of deficien-
cies that are present in the regulation of genetically modified
products.
In order to better understand these deficiencies, and to work
towards their cure, it is useful to categorize them. The following
four categories cover most of the regulatory problems concerning
transgenic products identified in this Article: gaps in regulation or
regulatory authority; overlaps in regulation or regulatory authority;
inconsistencies among agencies in their regulation of similarly
situated or identical products; and instances of agencies acting
outside of their areas of expertise.
Gaps are a problem because of the potential for harm to human
health or the environment. Overlaps cause a dead-weight loss on
multiple fronts: for the regulated industry which has to fulfill
2230 [Vol. 45:2167
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duplicative requirements; for government and, therefore, taxpayers
who must pay more than the necessary cost of regulation; and for
society for whom the development and commercialization of
transgenic products is inefficiently delayed. Inconsistencies are not
only irrational, but they also create a dead-weight loss for industry
trying to comply with the regulations, and they may delay the
development of valuable products. Lastly, instances of agencies
acting outside their areas of expertise are inefficient and unreason-
ably increase the risk posed to society by genetically modified
products. Each of these categories of deficiencies is discussed in
turn.
A. Regulatory Gaps
1. Gaps in Environmental Review
The most striking incidence of regulatory gaps with regard to
genetically modified products is the lack of EPA involvement in the
review and approval of numerous products that could have a
significant impact on the environment. As the salmon case study
demonstrates, the most significant risks posed by the introduction
of genetically modified fish are likely environmental. The EPA,
however, has determined that it does not have regulatory authority
over these products. The EPA also has no role in the approval or
field-testing and widespread planting of genetically modified plants
other than those modified to be pest-protected. Thus, the EPA is not
evaluating the potential impact of transgenic pharmaceutical-
producing, industrial compound-producing, herbicide-tolerant,
drought-tolerant, salinity-tolerant, virus-resistant, temperature-
tolerant, or disease-resistant plants on the environment.
That the majority of types of genetically modified plants are not
subject to environmental evaluation by the agency charged with
protecting the nation's environment is one problem. Whether the
plants are subjected to any appropriate environmental review is
another. APHIS does not conduct environmental assessments of
transgenic plants submitted through the notification process, 35 8
358. NRC 2002 REPORT, supra note 2, at 123. APHIS assumes genetically modified plants
released into the environment pursuant to the notification process to be environmentally safe
based upon the notification criteria and efforts required to minimize the chance of escape in
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which is currently the dominant route for the field-testing of new
genetically engineered plants. 59
Most troubling, the sufficiency of the environmental testing that
APHIS does engage in is questionable. The National Research
Council recently criticized certain APHIS environmental risk
assessments for "lack[ing] scientific rigor, balance, and transpar-
ency,"360 for containing an analysis that was "weak and inconsis-
tent,"" 1 for failing to evaluate potential impacts on nontarget
organisms, for failing to consider the interactions between multiple
transgenic traits, and for failing to utilize all available scientific
data and information." 2 APHIS also has been criticized for "relying
too heavily on existing scientific literature rather than requiring
applicants [for notification] to develop new experimental data"
relevant to the risks posed by the pertinent genetically modified
plants being reviewed.363 The EPA, with numerous experts trained
in and routinely performing environmental risk assessments,
almost assuredly would not have run into the same difficulties as
APHIS.36'
The concerns raised by the existing gaps in environmental review
will be exacerbated with next-generation biotechnology develop-
ments. In addition to transgenic fish, the FDA, not EPA, has
authority to review the environmental impacts of transgenic farm
animals modified to produce human drugs .1 5 The EPA also lacks
the field. Id.
359. See supra text accompanying note 333.
360. NRC 2002 REPORT, supra note 2, at 148.
361. Id. at 149.
362. Id. at 148-53, 160-66, 235. These criticisms were based on concerns that APHIS had
ignored certain scientific information it had reviewed, reached contradictory conclusions on
related analyses, relied on explanatory information as predictive, assumed that a lack of
reported problems was evidence that problems had not occurred, used data inconsistently,
failed to consider alternate options, and failed to consider interactions between different
traits. Id.
363. Kunich, supra note 134, at 840.
364. Nevertheless, the EPA has been criticized for environmental scientific failures of its
own, such as that demonstrated in the Monarch Butterfly case study. See supra Part III.C.;
see also EPA, REPORT: FIFRA SCIENTIFIC ADVISORY PANEL MEETING, SAP REPORT No. 99-06
(2000), available at http://www.epa.gov/scipoly/sap/1999/december/report.pdf(last visited Oct.
29, 2003) (criticizing the EPA's nontarget insect data requirements for genetically modified
pest-protected plants as being inadequate).
365. CASE STUDYNO. IV: FARM ANIMAL THAT PRODUCES HUMAN DRUGS, supra note 30, at
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authority over the environmental and ecological impacts of trans-
genic insects.66 The FDA and APHIS, not the EPA, are the agencies
that review the environmental impacts of pharmaceutical-
producing and industrial compound-producing plants.367  As
discussed above, whether APHIS has the capacity to conduct
sufficient environmental reviews is questionable. For similar
reasons, it is also unclear whether the FDA has the expertise
necessary to evaluate adequately the environmental risks posed by
biotechnology. 36" The FDA is not an environmental agency and lacks
expertise in critical areas concerning environmental impacts such
as ecology and evolutionary biology.369 Even if the FDA's environ-
mental assessments are adequate, it is unclear whether the FDA
possesses authority to deny certain applications on the basis of
environmental risk. 70 With new biotechnological developments fast
approaching, it is imperative that these environmental gaps be
closed.
2. Gaps Beyond Environmental Review
Regulatory gaps exist with respect to various agencies' authority
beyond the concerns raised by inadequate environmental review:
* It is unclear whether any agency has regulatory authority over
transgenic animals not intended for human food or to produce
human biologics.3 7'
366. ANIMAL BIOTECHNOLOGY, supra note 27, at 21.
367. CASE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN, supra note 73, at 52-53.
368. FUTURE FISH, supra note 25, at 54-55.
369. ANIMAL BIOTECHNOLOGY, supra note 27, at 114-15.
370. Gregory Jaffe, Coordinated Framework: Structure Needs an Overhaul, ENVTL. F.,
May/June 2002, at 24.
371. CASE STUDY NO. IV: FARM ANIMAL THAT PRODUCES HUMAN DRUGS, supra note 30, at
14. It is possible that APHIS could exercise authority pursuant to the Animal Health
Protection Act of 2002 (AHPA), 7 U.S.C. §§ 8301-8320 (1999 & Supp. 2003), to regulate
genetically modified animals, to the extent such animals may affect the health of livestock
(in much the same manner as APHIS regulates genetically modified plants based on their
plant pest threat). APHIS authority turns on the meaning of"disease" under AHPA, a term
to be defined by the Secretary of Agriculture. Id. § 8302(3). The Secretary may be able to
define disease in such a manner as to include genetic modification of animals, although this
would not be consistent with how the Secretary has defined the term previously, so whether
such a definition would survive judicial review is not clear. See, e.g., Definitions, 7 C.F.R. §
319.59-1 (2003) (defining "disease" in another agricultural context to include "its common
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" Once APHIS grants a petition for nonregulated status for
a transgenic plant, it no longer has any authority over the
plant or its progeny, for instance to monitor for unexpected
impacts. 2
" There is no requirement that a manufacturer notify the FDA
prior to the commercial introduction of a new genetically
modified product. 3 The FDA's promulgation two years ago of
a proposed regulation that would require notification recog-
nized that this gap was a problem.374
* EPA lacks regulatory authority over the growers of pest-
protected plants (its authority extends only to the producers of
such plants). 75
" Many APHIS requirements pertaining to preventing the
environmental release of transgenic plants do not cover the
release or movement of pollen.7 6
" Some genetically modified plants are not regulated on the
basis that their modified trait has been conventionally bred
into plants as well; this decision lacks scientific justification as
the genetic modification may cause different effects than those
caused by conventional breeding.
377
" APHIS lacks the statutory authority to regulate genetically
modified vertebrate plant pests and all organisms free of
genetic material from plant pests. 78
meaning [and] a disease agent which incites a disease"). In addition, the legislative history
of the AHPA is quite sparse and does not indicate that such a broad interpretation was
intended.
372. NRC 2002 REPORT, supra note 2, at 111, 233. In addition, if these progeny are mated
conventionally with other nonregulated transgenic plants carrying different transgenes, the
offspring also will be considered nonregulated, even though they will contain combinations
of transgenes never reviewed. These combinations could have pleiotropic effects. Id.
373. See supra Part IV.B.
374. See Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4709-12
(Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592) (proposed rule requiring premarket
notification of FDA of new genetically modified products).
375. TAYLOR & TICK, supra note 20, at 35.
376. NRC 2002 REPORT, supra note 2, at 109; APHIS, USER'S GUIDE FOR INTRODUCING
GENETICALLYENGINEEREDPLANTSAND MICROORGANISMS (1997) [hereinafter APHIS, USER'S
GUIDE], available at http://www.aphis.usda.gov/bbep/bp/usergd.html (last visited Apr. 7,
2004).
377. See NRC 2002 REPORT, supra note 2, at 86 (arguing that the failure to regulate crops
conventionally bred to contain certain traits does not justify not regulating crops genetically
engineered to contain the same trait).
378. Kunich, supra note 134, at 840.
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A cross-agency deficiency results from agencies' reliance on the
developer's planned use for their transgenic product as the trigger
for regulation, as opposed to basing regulation on the actual
characteristics of the product. For example, the EPA regulates a
transgenic plant under its pest-protected plant rules only if the
developer of the plant plans for it to be used for its pesticidal
effects. Thus, the EPA does not regulate a transgenic corn variety
modified to produce a known pesticide because the developer is
developing the corn for purposes other than pest resistance, in this
instance for medical diagnostic procedures.379 Similarly, for
purposes of determining whether field-testing of a transgenic plant
meets APHIS's notification criteria, a modification is only consid-
ered to be for a pharmaceutical use if clinical testing of the product
is proposed to the FDA.3 0 Thus, the developer of the product, as
opposed to APHIS, determines whether these types of transgenic
plants may be prohibited from notification approval.
Other gaps exist in APHIS' notification and permitting processes.
APHIS regulations state that a transgenic plant is not eligible for
testing or commercialization under the notification process if the
transgenes "[e]ncode substances that are known or likely to be
toxic to nontarget organisms.""' APHIS, however, defines "toxicity
to nontarget species" to apply only to species that feed on the
plant, not on dispersed plant parts, such as seeds, pollen, or plant
residue.382 Further, allergenicity is not one of the factors consid-
ered in approving a notification.3 83 As discussed above, under the
notification process, there is no limit to the amount of genetically
modified product that can be planted or commercialized.3'8 It
therefore would be possible under the notification process to grow
vast quantities of genetically engineered crops that have toxic plant
379. NRC 2002 REPoRT, supra note 2, at 180.
380. See APHIS, USER'S GUIDE, supra note 376.
381. Notification for the Introduction of Certain Regulated Articles, 7 C.F.R. §
340.3(bX4)(ii) (2003).
382. NRC 2002 REPORT, supra note 2, at 180-81.
383. Id. at 181.
384. See id. at 180-81.
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parts or may be allergenic. 385 This scenario appears to have
occurred in at least one instance. 386
Relatedly, under APHIS' permit process, APHIS can request
additional information from applicants, but cannot require the
requested information. 87 This deficiency may become critical as the
permit process is expected to be the primary route for the commer-
cial production of pharmaceutical-producing plants.
Regulatory gaps also exist with respect to the failure to properly
inform growers regarding the proper manner for use and contain-
ment of genetically modified crops. This failure is a root cause of the
contamination that occurred in both the ProdiGene and StarLink
scenarios. 8 Critics also have noted it as a problem with regard to
the proper planting of refuge areas so as to reduce the incidence of
pesticide resistance.389 Part of this deficiency stems from a failure
of agencies to exercise their full regulatory authority, and part
stems from regulators lacking authority over all entities involved
in the use of biotechnological products.
The numerous regulatory gaps identified above unnecessarily
increase the risk posed by genetically modified products. In
addition, they increase the likelihood of future high-profile trans-
genic product scares that could both reduce public trust in the
regulatory system and cause public opinion to coalesce against
genetically modified products. In either case, this would prevent
society from harvesting the optimum benefit of such products.
B. Regulatory Inconsistencies
The Coordinated Framework in 1986 identified two primary
priorities: that the agencies regulating genetically modified
products "adopt consistent definitions" of genetically modified
385. See id. at 181.
386. See id. at 180-81. This instance involves transgenic corn that produces the
glycoprotein avidin. Id. Avidin is potentially toxic to a broad array of organisms, both in the
field and after harvest. Id. The National Research Council"questions the wisdom of allowing
such plants to be grown under the streamlined notification system." Id. at 182.
387. NRC 2002 REPORT, supra note 2, at 110; see also Permits for the Introduction of a
Regulated Article, 7 C.F.R. § 340.4 (2003).
388. See supra Parts III.A, III.D.
389. See Bratspies, supra note 151, at 343-46 (discussing farmers' noncompliance with
refuge requirements); JAFFE, supra note 151, at 5-6 (providing data on the number of farms
out of compliance with refuge requirements in various states).
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organisms and that the agencies implement scientific reviews of
"comparable rigor" in their regulation of transgenic products.39
Neither priority has been met.
As a result of constraints created by primary reliance on statutes
that predate the advent of biotechnology, each of the three agencies
involved in the regulation of genetically modified products defines
identical regulatory constructs differently. Pest-protected plants
provide an example of a genetically modified product over which all
three agencies have regulatory authority. As Table 2 shows, each of
the agencies identify the regulated product and define the regulated
substance differently.
Table 2
Inconsistent Agency Definitions of
Pest-Protected Plants3 91
EPA USDA FDA
Regulated Plant-Incorporated Plant pest, regulated Food, feed, food
Product protectant article additive
Regulated Pesticidal Organism engineered Human food
Substance substance t contain sequences (whole or pro-
and genetic from plant pests cessed), animal
material feed
necessary for itsproduction
With respect to the second priority, the National Research
Council has specifically noted that the data on which the EPA and
APHIS base their analyses, and the scientific stringency with which
they conduct their analyses, are not comparably rigorous .392 APHIS'
risk assessment model may, in fact, bias it toward a finding of no
390. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302,23,303
(June 26, 1986).
391. NRC 2000 REPORT, supra note 4, at 159 (the table reproduced above has been
modified to reflect changes to agency definitions since the table was originally published).
The Coordinated Framework recognized from the outset that achieving consistent definitions
would not always be possible because of statutory constraints. See, e.g., 51 Fed. Reg. at
23,303 (stating that as a result of existing law, some definitions between agencies may seem
inconsistent). The failure to achieve this goal, therefore, is not necessarily the result of a lack
of effort on the agencies' part. It does, however, demonstrate the difficulty of promulgating
consistent regulations based on statutes enacted to handle different products.
392. See NRC 2000 REPORT, supra note 4, at 170-71.
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significant risk. 93 Thus, close to two decades after the Coordinated
Framework was established, neither of its priorities, both of which
were aimed at consistency, have been achieved.
Other substantial regulatory inconsistencies exist. Genetically
engineered pest-protected crops require premarket approval if
they are intended to be used for their pest-protection properties,
pursuant to EPA regulations;39' all other genetically engineered
food crops do not require premarket approval, including those crops
modified to express a known pesticide, so long as the developer is
producing the crop for another purpose, as they are subject to the
FDA's voluntary consultation process.39 This differentiation lacks
a sound basis in science, logic, or public policy.
In another example, when APHIS granted nonregulated status
to certain Bt crops, it did so on the basis that EPA regulations
would adequately prevent Bt resistance from arising in plant
pests.9  APHIS, however, granted nonregulated status prior to the
EPA's registration process, and did not follow-up to check that the
EPA had promulgated the anticipated regulations.397 Once APHIS
granted nonregulated status, manufacturers and growers had no
obligation to track or keep track of the genetically modified product,
thereby limiting the EPA's ability to gather data and information
on the impacts that APHIS expected the EPA to prevent through
regulation in the first instance.39
The regulatory inconsistencies identified in this section are
irrational and introduce substantial inefficiencies and unreasonable
risks into genetically modified product regulation.399
393. NRC 2002 REPORT, supra note 2, at 98.
394. See supra notes 313-16 and accompanying text.
395. See supra text accompanying notes 287-89; see also Affirmation of Generally
Recognized As Safe (GRAS) Status, 21 C.F.R. § 170.35 (2003).
396. See Bratspies, supra note 151, at 324-25.
397. See id. at 325.
398. See id. at 325-26.
399. Instances in which agencies' regulatory authority overlap, but the agencies have
reached different conclusions regarding the regulation of transgenic products, also
demonstrate inconsistencies. See infra Part V.D.
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C. Regulatory Inexperience
The StarLink corn case study highlights both an example of an
agency acting outside of its area of expertise and the potentially
disastrous effects of such action. Had the EPA, or likely the FDA,
been familiar with the nation's agricultural system, it would have
recognized that it was impossible for StarLink corn to be kept fully
segregated from corn used for human food.4 °0 This lack of knowl-
edge led to the most infamous transgenic food scare to date.
The numerous instances discussed above of agencies other than
the EPA bearing responsibility for the environmental review of
genetically modified products also present situations in which
agencies are acting in areas outside of their expertise. These
examples include: (1) the USDA and the FDA regulating the
environmental impact of genetically modified plants other than
those modified to produce their own pesticide,4 ' (2) the FDA
regulating the environmental impact of genetically modified fish
and animals,4 2 and (3) APHIS likely regulating the environmental
impact of transgenic insects."°3 The salmon case study demonstrates
the problems caused by the second deficiency. The first deficiency
has led to difficulties of its own. For instance, APHIS' analysis of
the likelihood of virus-resistant genes spreading from squash to
weedy relatives has been criticized for not being well supported by
scientific studies and for lacking necessary data.' In part, these
deficiencies were perceived to come about as the result of "inade-
quate expertise [at APHIS] in population genetics."'0 5
Lack of expertise and experience has led to other problems. The
Monarch butterfly case study" reveals that agencies have failed to
fully grasp the potential varied impact of genetically engineered
products. In this instance, regardless of whether the Bt pollen
400. See supra notes 217-18 and accompanying text.
401. See supra notes 295-96, 323 and accompanying text.
402. See supra notes 297-99 and accompanying text.
403. See supra notes 345-46 and accompanying text.
404. See NRC 2002 REPORT, supra note 2, at 134-35; NRC 2000 REPORT, supra note 4, at
122-25.
405. NRC 2002 REPORT, supra note 2, at 134.
406. See supra Part III.C.
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actually poses a risk, the EPA's assumptions concerning the threat
of transgenic pollen were scientifically unsound.0 7
Perhaps similarly stemming from inexperience, isolation dis-
tances required by APHIS for test plots of transgenic crops have
been criticized as not being scientifically justifiable.0 8 APHIS
appears to have derived a required isolation distance, intended to
establish a zero tolerance for contamination simply by doubling the
isolation distance used by the USDA in another regulatory context
in which a contamination level of 0.1% was acceptable. 9 There was
no evidence that doubling the isolation distance would reduce the
anticipated level of contamination from 0.1% to zero."" As discussed
above, long distance pollen flow is poorly understood."' Pollen does
appear to travel at least several kilometers, many times the
isolation distance at issue. 412 Some have cited contamination by
pollen flow as part of the cause of the StarLink fiasco.""
These problems of regulatory inexperience and agencies acting in
areas beyond their expertise not only result in significant inefficien-
cies, but also dramatically and unnecessarily increase the risk
posed by genetically modified products.
D. Regulatory Overlaps
Several types of regulatory overlap exist in the current regulatory
structure. The first overlap concerns situations in which different
agencies have authority over similar issues. For example, the EPA
addresses food safety issues associated with plants genetically
modified to produce their own pesticide, 4 4 whereas the FDA
407. See supra notes 245-50 and accompanying text.
408. See NRC 2002 REPORT, supra note 2, at 125.
409. See id. at 125.
410. Id.
411. See supra note 125 and accompanying text.
412. Compare Minimum Land, Isolation, Field, and Seed Standards, 7 C.F.R. § 201.76
(2003) (stating the required isolation distances for various crops), with NRC 2000 REPORT,
supra note. 4, at 91 (discussing a study which found pollen dispersed as far as three
kilometers from its source). Currently proposed regulations would increase the buffer zone
for corn to between a half mile and one mile, depending on certain other factors. See supra
note 342.
.413. See, e.g., McGarity, supra note 8, at 487 ("Still others claimed that they had
innocently sold elevators StarLink®-contaminated corn when the corn they planted became
cross-fertilized by StarLink* corn from neighboring fields.").
414. See supra notes 313-16 and accompanying text.
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addresses similar food safety issues for all other genetically
modified plants.4 1 ' There is no scientific rationale for this distinc-
tion. It is the result of the historical accident of transgenic pest-
protected plants falling within FIFRA's statutory language.
Similarly, both the EPA and APHIS conduct overlapping
reviews regarding the impact of pest-protected plants on nontarget
species. The EPA studied the potential impact of Bt corn on
butterflies to determine the effect of the pesticide on nontarget
species, whereas APHIS studied the potential impact of Bt corn on
butterflies to determine whether it would lead to a reduced
butterfly population. 416 A reduced butterfly population was
considered a potential plant pest risk as it could allow greater
growth of weeds that the butterflies feed on."7 In each instance, the
result is that regulatory expertise and effort is inefficiently
duplicated in multiple agencies.
A second type of regulatory overlap occurs where multiple
agencies request the same information about the same biotechno-
logical product, but do not share the information. For instance,
though APHIS reviews genetically modified herbicide-tolerant
plants and the EPA reviews the herbicide that will be applied, these
reviews have not been coordinated."5
The worst case scenario for overlaps is for agencies to reach
different conclusions concerning the same product. Such a result
has occurred. Both APHIS and the EPA reviewed the potential for
transgenic cotton to cross with wild cotton in parts of the United
States. APHIS concluded that "[n]one of the relatives of cotton
found in the United States ... show any definite weedy tenden-
415. See supra notes 295-96 and accompanying text.
416. See CASE STuDY No. II: BT-MAIZE, supra note 36, at 32 (presenting an example of
overlap between the EPA and APHIS); NRC 2002 REPORT, supra note 2, at 72-74; NRC 2000
REPORT, supra note 4, at 163-65 (concluding that there is substantial overlap in this area);
see also Regulations Under FIFRA, supra note 296, 66 Fed. Reg. at 37,775 (recognizing the
potential for duplicative regulation in this area). In certain instances, it has been unclear
whether APHIS was acting independently of the EPA, possibly producing differing levels of
regulatory scrutiny, or whether APHIS lacked requisite expertise and was relying on the
EPA's determinations. See NRC 2002 REPORT, supra note 2, at 157.
417. See NRC 2002 REPORT, supra note 2, at 72.
418. See CASE STUDY No. III: HERBICIDE-TOLERANT SOYBEAN, supra note 73, at 17-18
(stating that although APHIS and the EPA are working on coordinating efforts, currently,
there are no formal exchanges between the two agencies on this subject).
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cies."419 EPA, conversely, found that there would be a risk of
transgenic cotton crossing with species of wild cotton in southern
Florida, southern Arizona, and Hawaii.42
Regulatory overlap in the area of genetically modified products
has led to inefficient duplicative expertise and review, and to
conflicting conclusions.
VI. THE CAUSE AND THE CURE OF THE REGULATORY DEFICIENCIES
As demonstrated above, under the existing statutory and
regulatory structure governing genetically modified products,
administrative agencies lack the necessary and proper authority,
act in areas outside their expertise, and regulate in conflicting and
inconsistent manners. This section discusses the causes of these
problems and provides proposals for curing them.
A. The Coordinated Framework Revisited
The cause of many of the deficiencies identified can be traced to
the 1986 Coordinated Framework for Regulation of Biotechnology.
Specifically, the deficiencies can be traced to two problematic
presumptions that formed the Coordinated Framework's founda-
tion: (1) that the techniques of biotechnology are not inherently
risky, and (2) that biotechnology should not be regulated as a
process-that is, that the products of biotechnology should be
regulated in the same manner as conventionally created products.41
Though both of these presumptions contain significant truthful
elements, an absolutist statement of and belief in them has had
long term deleterious effects.
The consequence of these presumptions is the existing statutory
scheme in which bioengineered products are regulated under laws
419. JOHN H. PAYNE, USDA/APHIS PETITION 97-013-01P FOR DETERMINATION OF
NONREGULATED STATUS FOR EVENTS 31807 AND 31808 COTrON: ENVIRONMENTAL ASSESSMENT
AND FINDING OF No SIGNIFICANT IMPACT (1997), available at http://www.aphis.usda.gov/brs/
decdocs/9701301pea.HTM (last visited Apr. 7, 2004).
420. EPA, BT PLANT-PESTICIDES BIOPESTICIDES REGISTRATION ACTION DOCUMENT
IIC9-IIC10 (2000), available at http:/Avww.epa.gov/scipoly/sap/2000/October/brad3-
enviroassessment.pdf (last visited Apr. 7, 2003).
421. Coordinated Framework for Regulation ofBiotechnology, 51 Fed. Reg. 23,302,23,303,
23,309, 23,336 (June 26, 1986).
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enacted long before such products were considered possible. The
decision to regulate transgenic products under archaic laws has led
to many of the gaps, inconsistencies, inexperience, and overlaps
discussed above. It has forced agencies to fit transgenic products
into statutory and regulatory boxes that were not designed to
handle them.4 22 It has led agencies to assert regulatory authority
over certain products where such agencies are not the most efficient
regulators, either because they are not used to regulating a given
type of product or because they lack the personnel, institutional
knowledge, or capacity to regulate it.
Another result of the Coordinated Framework paradigm has been
multiple failures on the part of regulatory agencies to recognize that
genetically modified products sometimes do create new and
different issues than those raised by the conventional products they
routinely regulate. The Coordinated Framework's conclusions that
genetically modified products should not be regulated based on the
process by which they are created, and that no new statutory
authority is necessary to regulate them, have led regulators to
believe that there are no new risks posed by transgenic products,
and perhaps to believe that they are not significantly risky at all.42
These conclusions also have led to an agency culture of passivity in
regulation. Agencies generally have appeared complacent with
transgenic product risks, waiting for problems to occur before
taking protective action. This complacency is likely due to a belief
that these products do not cause any new or different risks. The
StarLink corn and Monarch butterfly scenarios are prime examples
of the danger of regulatory blinders in this regard.424
The Coordinated Framework's central precept, that the process
of genetic modification is not itself inherently risky and there-
fore that the process should not serve as a trigger for regulation,
was repeated explicitly in various federal reports, at least
through 1992.425 It has never been officially disavowed. Our current
422. See, e.g., supra notes 308-09 and accompanying text (stating that FIFRA was enacted
to regulate chemical substances, but is now being used to regulate genetic material in
transgemic plants).
423. See Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. at 23,303,
23,309, 23,336 (asserting that the new regulations are not needed to address genetically
modified products).
424. See supra Parts III.A, III.C.
425. See supra note 273 and accompanying text.
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understanding of genetic modification and the actual manner in
which it is now regulated, however, demonstrate that this perspec-
tive is flawed.
Each of the three main agencies charged with the regulation of
genetically modified products now has determined independently
that the assumptions of the Coordinated Framework are incorrect.
These conclusions are demonstrated in each agency's current use of
the process of genetic modification itself as a trigger for regulation.
APHIS regulation pursuant to the PPA is limited to "[any
organism which has been altered or produced through genetic
engineering. "426 Thus, APHIS regulates organisms based on the
process by which they were created, not based on the product.
Similarly, the EPA's 2001 pest-protected plant regulations regulate
plants based on whether they were derived through genetic
engineering. 427 The regulations specifically apply only to those pest-
protected plants created by genetic engineering, exempting similar,
and theoretically even identical, plants derived through conven-
tional breeding. 2 '
Finally, in proposed biotechnology regulations in 2001, the FDA
stated that, relative to traditional crop breeding, genetic modifica-
tion increases the introduction of specific new substances into foods,
increases the directed modification of the composition of foods, and
increases the speed at which traits can be introduced into food.429
The FDA concluded "that the products of [biotechnology] are likely
in some cases to present more complex safety and regulatory issues
than seen to date."430 The FDA therefore proposed a premarket
notification requirement for bioengineered food.431' This proposed
regulation is based on the biotechnology process, not the product.
Echoing the three agencies' conclusions, the National Research
Council also has determined that there is a logical scientific basis
426. Definitions, 7 C.F.R. § 340.1 (2003).
427. Regulations Under FIFRA, supra note 296,66 Fed. Reg. at 37,777-78; Exemption for
Residues Derived Through Conventional Breeding, supra note 296, 66 Fed. Reg. at 37,830.
428. See supra note 427.
429. See Premarket Notice Concerning Bioengineered Foods, 66 Fed. Reg. 4706, 4709
(proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192, 592).
430. Id.
431. See id. at 4712-13.
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for regulating all genetically engineered crops based on the process
by which they were created."32
APHIS, the EPA, the FDA, and the National Research Council all
have determined that certain genetically modified products should
be regulated based on the process by which they were created.
These determinations reveal that the foundational presumptions of
the Coordinated Framework, and the basis for the current system
of regulation, are unwarranted.
Other false presumptions in the Coordinated Framework
further demonstrate that the regulatory system envisioned in
1986 and still in place today is unworkable. The FDA concluded in
the Coordinated Framework that, "new marketing applications
will be required for most products manufactured using new
biotechnology." 3 As discussed above, the FDA has not required a
new marketing application for a single one of the genetically
modified food products introduced to date.434 Similarly demonstrat-
ing limited foresight, the Coordinated Framework failed to pre-
scribe how transgenic pest-protected plants would be regulated,
apparently because such products were not yet on the regulators'
radar.435 Such products, however, were field tested just one year
after the Coordinated Framework was promulgated and are now
one of the dominant commercial genetically modified products.3 6
Moreover, the Coordinated Framework failed to provide adequate
regulatory structure for transgenic fish and shellfish.3 7
The governing paradigm of the Coordinated Framework has
proven false and has been disavowed implicitly by the regula-
tory agencies charged with implementing it. The Coordinated
Framework also has proven incapable of adapting to certain
biotechnology advances. Despite these failures, the Coordinated
Framework continues to serve as the operational basis for the
regulation of genetically modified products today. That the current
statutory and regulatory structure cannot effectively handle
432. See NRC 2002 REPORT, supra note 2, at 52, 82-83.
433. Coordinated Framework for Regulation ofBiotechnology, 51 Fed. Reg. 23,302,23,309
(June 26, 1986).
434. See supra notes 288-89 and accompanying text.
435. See NRC 2000 REPORT, supra note 4, at 26.
436. See id.
437. FUTURE FISH, supra note 25, at 37 (noting that the Coordinated Framework failed to
"specify the lead agency for transgenic fish and other [transgenic] aquatic organisms").
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existing biotechnology products leaves little doubt that as biotech-
nology advances to next-generation products, introducing additional
new issues and concerns, achieving proper regulation under the
existing system and statutes will be even more problematic. Based
on these recognitions, and on the numerous regulatory deficiencies
cited in this Article, it is time to replace the Coordinated Frame-
work and the current regulatory system with a substantially more
efficient and reasonably protective structure.
B. Proposed Statutory and Regulatory Changes
The problems identified throughout this Article point directly to
many of the solutions that must be implemented in a new statutory
and regulatory structure for regulating genetically modified
products. These solutions fall into two broad categories: closing
regulatory and statutory gaps, and overhauling the division of
regulatory responsibility.
1. Closing Regulatory and Statutory Gaps
Numerous statutory and regulatory gaps must be closed to
provide an adequate regulatory structure for genetically modified
products. The most critical gaps exist with respect to environmental
protection and next-generation biotechnology.43 The EPA should be
given statutory authority to evaluate the environmental risk posed
by genetically modified products. The genetically modified salmon
case study demonstrates the critical nature of this authority with
respect to transgenic fish.439 Transgenic insects similarly pose
environmental concerns.44 ° Although the environmental risk posed
by livestock is lower because of the reduced risk of escape,44' the
EPA still should have authority over all genetically modified
animals. The EPA also should be able to consider the environmental
impact of transgenic plants other than those modified to be pest
protected because of the risks of gene flow and invasiveness." 2
438. See supra Part V.A.1.
439. See supra Part III.B.
440. See supra note 170 and accompanying text.
441. See supra note 171 and accompanying text.
442. Examples of these types of plants would include, for example, pharmaceutical-
producing, industrial compound-producing, herbicide-tolerant, drought-tolerant, salinity-
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Currently, APHIS' review of releases, which focuses on impacts to
agriculture, is the only review of the environmental impact of these
plants. The vast majority of this review consists of the notification
process.443
Expanded EPA environmental review does not mean that
industry expenses will significantly increase, which could slow or
otherwise impede biotechnology growth. First, EPA review will
likely indicate that many types of transgenic products are not
significant environmental threats and can be handled through some
sort of notification process. 4" It should be the EPA that makes this
environmental determination, however, not an agency that lacks
environmental expertise or resources, or no agency at all. Second,
for products of greater concern, EPA expertise should allow it to
reach final determinations faster and more predictably than the
current arrangement, with concomitant benefits for biotechnology
developers.
The second major gap area, concerning next-generation biotech-
nology, also must be addressed. Regulations governing genetically
modified animals for uses other than as human food or to produce
human biologics must be promulgated. This is particularly impor-
tant, as several animals modified to produce animal or veterinary
biological products are anticipated in the near future.4 5 As
discussed above, the AHPA may provide APHIS with a basis for
regulatory authority over such transgenic animals, but such
authority is both unclear and has not been asserted.446 Similarly,
statutory authority for and regulations governing the research and
commercialization of transgenic insects also needs to be developed.
The lack of a clear regulatory structure in these next-generation
areas may impede scientific progress.
Additional regulatory gaps must be filled within each of the three
agencies. All agencies should regulate based on the potential risks
of a given product, not based on how a developer classifies the
product. APHIS should be given authority to monitor transgenic
tolerant, virus-resistant, temperature-tolerant, and disease-resistant plants.
443. See supra notes 332-39 and accompanying text.
444. See, e.g., NRC 2002 REPORT, supra note 2, at 83 (stating that most genetic
introductions will not pose a threat to the environment).
445. See CASE STUDY No. IV: FARM ANIMAL THAT PRODUCES HUMAN DRUGS, supra note
30, at 14.
446. See supra note 371.
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plants after they have been granted nonregulated status to provide
for postmarket monitoring or oversight in order to be able to detect
and correct any unanticipated problems.447
The FDA should implement its 2001 proposed regulations to
make notification of the commercialization of new genetically
modified food products mandatory. Though the FDA believes it has
been voluntarily notified of all such products introduced to date,448
as the role of biotechnology expands, not all developers will
necessarily take this step. Absent knowledge of a particular genetic
modification, the FDA has no method for monitoring whether food
products have been genetically modified or contain any genetically
modified component.449
Growers of genetically modified pest-protected plants should be
made accountable to the EPA for the manner of use and contain-
ment of the transgenic plants. Currently, only product developers
are accountable to the EPA, and grower accountability is attempted
through contractual agreements between the producer and the
grower required by the EPA.450 The StarLink451 and ProdiGene
452
cases, as well as recent surveys of grower compliance,453 amply
demonstrate that such informal control is not sufficient.
Most of the other statutory and regulatory gaps identified above
have clear fixes and will not be discussed further.454 A final point
with respect to regulatory gaps should be made. Some gaps are not
the result of statutory or regulatory deficiencies but result in part
from a lack of scientific knowledge. Long-distance pollen flow is a
prime example. It is a poorly understood phenomenon, but it has a
significant effect on how numerous genetically modified crops and
pharmaceutical-producing and industrial compound-producing
447. See TAYLOR & TICK, supra note 20, at 44 (stating that the need for postmarket
oversight is likely to change with genetic products).
448. See supra note 292 and accompanying text.
449. See TAYLOR & TICK, supra note 20, at 54 (stating that agencies today only respond
to specific safety concerns that arise, rather than knowing which products are genetically
modified).
450. See id. at 34-36. The grower is therefore under no legal obligation to the EPA to
comply with any planting restrictions. See id.
451. See supra Part III.A.
452. See supra Part III.D.
453. JAFFE, supra note 151, at 5-6 (presenting data on refuge requirement compliance
deficiencies on corn farms).
454. See supra Part V.A.
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plants should be handled. One solution in these instances is to
create a market for the missing scientific data. If, for instance,
agencies began to require data on pollen flow in relation to regula-
tory approval for planting transgenic plants under certain condi-
tions, understanding of this critical parameter would improve
rapidly.455 Improved scientific understanding will allow for more
finely tuned regulation, which in turn will result in savings for
industry, as it will not have to comply with regulations that are
inefficiently overprotective due to a lack of information.
2. Overhauling the Division of Regulatory Responsibility
In order to maximize the social welfare improvements provided
by genetically modified products, instances of regulatory agencies
acting outside their areas of expertise, regulatory overlap, and
inconsistent and sometimes conflicting regulation must be reme-
died. All three of these problems can be substantially ameliorated
by shifting the division of regulatory authority over genetically
modified products from the current one, based haphazardly on
preexisting statutes, to a division based upon each agency's
expertise and general mandate. Thus, the FDA should bear
responsibility for the human health risks posed by genetically
modified plants or animals intended for use as human food or
pharmaceuticals; the EPA should take responsibility for evaluating
the environmental risks posed by transgenic products; and the
USDA should regulate the impact of genetically engineered
products on agricultural crops and livestock.
455. For example, Comprehensive Environmental Response, Compensation and Liability
Act (CERCLA) liability and potential liability created a market for data on groundwater
chemistry and hydrology. See James Salzman, Valuing Ecosystem Services, 24 ECOLOGY
L.Q. 887, 898 (1997) (reviewing NATURE'S SERVICES: SOCIETAL DEPENDENCE ON NATURAL
ECOSYSTEMS (Gretchen C. Daily ed., 1997)). Wetlands regulations created a market for data
on wetlands vegetation and hydrology. Id. Both of these needs led to a much better
understanding of the respective scientific issues.
Requiring industry to provide scientific information raises concerns about potential
industry bias in the reporting of data. The experience with hazardous and toxic waste site
cleanup, wetlands protection, endangered species surveys, and other types ofenvironmental
assessment requirements has demonstrated that regulatory agency review of industry-
provided data can help to ensure accuracy and lead to greater scientific knowledge in the
long run. See id. (discussing the improvement in the understanding of scientific matters due
to CERCLA and wetlands regulation).
2249
WILLIAM AND MARY LAW REVIEW
This division of regulatory authority not only is inherently
logical, but also provides the added benefits of increased efficiency,
greater human health and environmental protection, and economic
savings. Placing regulatory authority for particular risks in the
hands of the agency with the most expertise, experience, and
relevant resources will best guarantee that the risk is properly
evaluated and protected against. It will do so as quickly and
inexpensively as possible. Such action also will clear up instances
of regulatory inconsistency and overlap because a given risk will
only be evaluated by a single agency.
One concern with such a solution may be that a single transgenic
product could be regulated by multiple agencies if it presents
multiple types of risks; that is, there will be certain types of overlap
even under the proposed changes to the regulatory system. Because
genetically modified products raise varied types of risk, it is
inevitable that there will be some overlap in agency responsibility
under any regulatory system. The nature of legislation and
regulation themselves necessarily create overlaps and gaps, as well
as overregulation and underregulation. Legislation and regulation
require the categorization of problems or concerns in some manner.
Inevitably certain issues will arise that do not fit neatly into the
regulatory boxes created. Where these issues fall through the
cracks, there will be a regulatory gap; where they fall within
multiple boxes, there will be regulatory overlap. For efficiency and
economic purposes, one goal of regulation should be to minimize
these regulatory problems, while still maintaining adequate
protection. The proposals contained in this Article seek to minimize
regulatory gaps and greatly reduce the existing amount of regula-
tory overlap.
In addition, the expense of any overlap that results from this
proposal can be reduced by requiring the agencies to coordinate
their actions; for instance, by designating a lead agency based on
the most significant risk and requiring only a single developer
submission covering all pertinent information for a given product.
Under the existing regulatory system, a lead agency is usually, but
not always, designated for transgenic products that fall within
multiple agencies' authority. Such designation, however, is not
necessarily based on the type of risk presented and generally has
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not resulted in coordinated information submission requirements.456
For instance, both the EPA and the USDA require similar informa-
tion submissions on pest-protected plants.
The requirements proposed here also would force better commu-
nication among the various agencies, a problem that has plagued
biotechnology regulation since its inception,457 with resulting
increases in efficiency for industry and savings for taxpayers. Most
importantly, placing responsibility for a given risk with the agency
best equipped to regulate it removes the cost of paying for unneces-
sary, duplicative areas of expertise in multiple agencies, signifi-
cantly reducing the expense of regulation.
It is worth noting that in most areas of regulation in the United
States, the agency that has regulatory authority over a given
product is usually the agency with the most expertise in handling
the type of risk presented by the product. Genetically modified
product regulation, however, is a product of the historical accident
of transgenic products being squeezed into statutory definitions not
intended for them. Numerous inefficiencies could be cleared up and
numerous risks protected against by shifting regulatory authority
to a risk-based approach.
C. Debunking Common Critiques of Regulatory Change
Optimizing social welfare through improving the regulation of
genetically modified products is not a universally accepted solution.
Many commentators contend that the current statutory and
regulatory structure governing genetically modified products should
not be changed. Most critiques of more efficient and reasonably
protective regulation fall into one of several camps: that biotechnol-
ogy products are not different than, or do not present different risks
456. See Wilson Huhn, Three Legal Frameworks for Regulating Genetic Technology, J.
CONTEMP. HEALTHL. &POL'Y, 1, 29 (2002) ("Despite its name, the [Coordinated Framework]
has often lacked coordination.").
457. See, e.g., Recommendations and Statement of the Administrative Conference
Regarding Administrative Practice and Procedure, 54 Fed. Reg. 53,493 (Dec. 29, 1989)
(recommending numerous steps to improve interagency coordination in the regulation of
biotechnology); CASE STUDYNO. III: HERBICIDE-TOLERANT SOYBEAN, supra note 73, at 17-18
(noting that the EPA and APHIS have not coordinated herbicide-tolerant plant review); NRC
2000 REPORT, supra note 4, at 16 (recommending improving interagency coordination in the
regulation of biotechnology).
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than, conventional products; that regulation based on process would
treat like products differently; or that market forces will adequately
protect society from the risks of genetically modified products.
Though each of these contentions contains grains of truth, none
withstand rigorous analysis, as discussed below.
1. Are Genetically Modified Product Risks New?
The most common critique of the need to regulate genetically
modified products differently is likely that the risks posed to human
health and the environment by such products are no different than
those posed by conventionally bred crops, and therefore no special
regulation is necessary. Supporting this contention, in 1987 the
National Research Council stated, "[t]here is no strict dichotomy
between, or new categories of, the health and environmental risks
that might be posed by transgenic and conventional pest-protected
plants."458 The argument against specific genetically modified
product regulation, however, relies on loose terminology and takes
the National Research Council findings out of context.
In a limited sense, it is true that certain risks from genetically
engineered products are not different in kind than those posed by
conventional products. For instance, both types of modification can
lead to undesirable traits in the final product, can create unex-
pected results, and can result in gene flow to other organisms. 59
Just like genetically modified products, some people have allergic
reactions to conventional crops and conventional species can be an
invasive threat to native species. The quality and quantity of risks
posed by genetically modified products, however, are different in
certain critical respects from those posed by conventional products,
and it is these differences that require special attention.
The differences between transgenic and conventional product
risks occur primarily because biotechnology allows a much broader
array of genetic traits to be incorporated into a new organism than
458. NRC 2000 REPORT, supra note 4, at 43; see also NRC 2002 REPORT, supra note 2, at
29, 52 (noting that "[t]ransgenic crops do not pose unique categories or kinds of
environmental hazards," and, "it is not possible to qualitatively differentiate the general
environmental risk associated with the release of conventionally bred crop cultivars and the
introduction of new species").
459. NRC 2002 REPORT, supra note 2, at 48-49; ROYAL SOc'YOF CAN., supra note 5, at 124.
2252 [Vol. 45:2167
20041 GENETICALLY MODIFIED PLANTS AND ANIMALS
is possible through conventional breeding.460 Conventional breeding
is limited by the available genetic variability in the target organism
and its sexually compatible relatives. "The great potential, as well
as risk, of genetic engineering is that it removes those limits."46'
Genetic engineering allows the introduction of new traits that could
never have been incorporated before.46 2 Additionally, the highly
domesticated characteristics of some conventional crops are
believed to pose fewer environmental hazards than transgenic
crops.463 Initial experiences with genetically modified animals also
demonstrate this difference. Naturally occurring mutations appear
to place certain limitations on the amount of change in convention-
ally bred animals, while genetic engineering may not. For instance,
naturally modified salmon appear to be limited to four times their
normal size, while transgenic salmon have grown up to a mean size
of eleven times normal at certain ages.'64
The degree of change in genetic information resulting from
modification, whether conventional or biotechnological, can be
measured along two dimensions: by the number of genetic changes
made and by the taxonomic distance between the donor and host
organisms. Changes in the former manner will vary in extent for
both biotechnological and conventional modification. Changes in the
latter manner, however, are much greater for genetic engineering
than for conventional hybridization. As a result, the National
Research Council found, in its most recent report on the subject,
that genetic engineering can "introduce specific traits or combina-
tions of traits that pose unique risks."46 For example, transgenes
that introduce natural pesticides from nonplant sources create new
exposures and therefore new concerns. 66 On this basis, the Council
460. NRC 2002REPORT, supra note 2, at 220; Premarket Notice Concerning Bioengineered
Foods, 66 Fed. Reg. 4706,4709 (proposed Jan. 18, 2001) (to be codified at 21 C.F.R. pts. 192,
592).
461. Wolfenbarger & Phifer, supra note 57, at 2092; see also NRC 2002 REPORT, supra note
2, at 36-37 (noting this difference).
462. NRC 2002 REPORT, supra note 2, at 48 ("What makes the transgenic approach
particularly new is the potential to incorporate novel traits.").
463. Id. at 36.
464. ANIMAL BIOTECHNOLOGY, supra note 27, at 79-80.
465. NRC 2002 REPORT, supra note 2, at 48.
466. NRC 2000 REPORT, supra note 4, at 57.
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concluded, "there are good arguments for regulating all transgenic
crops. "467
Thus, while people are allergic to conventional foods and
conventional foods contain toxins, genetic engineering may
introduce a more diverse or far greater amount of different
allergens and toxins. As genetically modified products become more
pervasive, the number of these introductions and the speed with
which they occur will increase. For similar reasons, though the
categories of risk posed by potential antibiotic resistance, pesticide
resistance, gene flow, or invasiveness may not be new, the risks in
certain areas are significantly higher, and can be different in kind
from those regulators have faced before.
The differences in risk between biotechnological and conventional
modification are even more pronounced for next-generation
biotechnology products. Consider first agricultural crops. The
experience with the transgenic varieties commercialized to date are
expected to provide only "a very limited basis for predicting" the
environmental risks posed by future transgenic plants, which are
considered to be on a "wholly different order" than those currently
posed.468 The new risks posed by potential widespread use of
pharmaceutical-producing and industrial compound-producing
plants, and by the future introduction of genetically modified fish,
insects, and livestock discussed throughout this Article demonstrate
the necessity of particularized transgenic product regulation.
2. Should Regulation Be Based upon the Product or the
Process?
A second common critique of the conclusion that genetically
modified products should be regulated as such is that it could lead
467. NRC 2002 REPORT, supra note 2, at 52; see also CEQ AND OSTP ASSESSMENT, supra
note 49, at 3. As the National Research Council noted, this conclusion does not imply that
all transgenic crops are dangerous. In fact, most may not need heavy oversight. But,
regulation is necessary to weed those that need a second look from those that do not. NRC
2002 REPORT, supra note 2, at 52.
It is possible that a greater understanding of the risks posed by transgenic plants will
indicate that conventional crops have not been regulated adequately. Admittedly, this would
place governmental regulators in a difficult spot. See id. at 19. Inadequate regulation of
earlier products, however, is a poor reason not to regulate later technologies adequately.
468. NRC 2002 REPORT, supra note 2, at 220, 246.
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to the anomalous result of two identical products (one created
though conventional breeding, one through genetic engineering)
being regulated differently. Though this concern resonates in theory
(identical products should be regulated identically), it fails to
withstand a practical analysis.
First, genetic modification increases the introduction of new
substances, increases the speed at which traits are introduced, and
leads to the introduction of transgenes from taxonomically very
different organisms. As a result, the probability of certain risks
being created by the process of genetic engineering is substantially
greater than by the process of conventional breeding. Regulation
based on the process of creation is rational because certain geneti-
cally modified products are more likely to pose certain risks than
conventional products.
Second, all three agencies regulating genetically modified plants
and animals, based on their practical experience, as well as the
National Research Council, have concluded that at least certain of
their regulatory regimes should be based upon the process (genetic
engineering) by which a given product was created." 9
Third, many conventionally bred products, for example, most
farm crops, have been unregulated since time immemorial.
Instituting a regulatory regime to cover all crops would be far more
difficult than instituting one to cover transgenic products, if not
impossible. Faced with the choice between implementing a regula-
tory system that will better protect society from the risks posed by
genetically modified products, even if it fails to regulate a small
number of similarly risky conventional products, and no regulatory
protection at all, the former is highly preferable.
3. Should Protection Be Left to the Market?
The last category of critique of genetically modified product
regulation is the contention that market forces will adequately
protect society from the risks of these products, and will do so more
efficiently than regulation. The existence of substantial market
failures and inefficiencies in this area, however, demonstrates that
such a critique is unsupportable.
469. See supra notes 426-33 and accompanying text.
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First, numerous externalities are inherent in the risks posed by
genetically modified plants and animals. Under a market approach,
transgenic product developers and growers would not take into
account the full social cost of most environmental impacts caused
by their products. For instance, absent widespread natural resource
disasters, it is unlikely that product developers and growers would
bear the burden of ecological damage caused by gene flow, invasive
plants, reduction in biodiversity, or impacts on nontarget organ-
isms. The tort system and other legal remedies may force develop-
ers and growers to bear the cost of certain human health impacts,
but problems with scientific proof of causation would introduce
externalities here as well.
Second, many of the risks posed by biotechnology would only
result in latent harm, to the extent they cause harm, either to
human health or the environment. In addition, causation will often
be a matter of probability. Two issues that the American tort
system has significant difficulty handling are harms not known
until a long time after they were caused and issues of probability in
causation.470 Thus, injured parties would have a hard time recover-
ing proper damages.
Third, in bad-case scenarios involving significant or widespread
harm, the damage caused may be so great that the party responsi-
ble will have insufficient resources to compensate injured parties or
society adequately. Relatedly, because many injuries caused would
result only in latent harms, the party responsible may no longer be
able to be located or may no longer be a going concern.
Market forces do not provide an efficient or adequate means of
controlling or regulating biotechnology because of the market
failures and externalities introduced by the potential harmful
470. See generally JOSEPH SANDERS, BENDECTIN ON TRIAL: A STUDY OF MASS TORT
LITIGATION (1998) (discussing these tort system problems in connection with the Bendectin
litigation); PETER H. SCHUcK, AGENT ORANGE ON TRIAL: MASS ToXIc DISASTERS IN THE
COURTS (1986) (discussing these tort system problems in connection with various toxic tort
litigation). That the tort system generally has a difficult time handling issues where
causation is a matter of probability and the harm is latent does not mean that it has no role
in the regulation of genetically modified products. Should transgenic products cause
widespread harm, the tort system would play an essential part in assigning and apportioning
liability, as has occurred in the StarLink corn case. Whether the tort system will do so
efficiently, however, is a matter of much conjecture.
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effects of genetically modified products. Revising the current federal
statutory and regulatory framework is necessary.
CONCLUSION
Since this country's creation, the federal government often has
had to handle new legal and regulatory issues arising as the result
of technological innovation. For example, the invention and
introduction of the steamboat in the nineteenth century led to new
issues regarding steam engine safety and liability for injury caused
by exploding boilers,"7 and the development and use of new
industrial substances in the twentieth century led to myriad new
issues concerning the protection of human health and the environ-
ment from toxic substances and hazardous waste. 72 Each time a
new technological advance creates new concerns, the issue arises of
whether to govern the new technology under the existing system
and rules or to create a new system and rules. This issue is
significantly complicated by the fact that technological advances are
often, almost by definition, at the forefront of scientific knowledge,
and therefore not only are usually incomprehensible to the
layperson, but may not be fully, or even well, understood by the
most advanced experts in the relevant field. In the case of the
steamboat, it took decades to determine whether boiler explosions
were random or the result of negligence. 7 ' In the case of toxic
substances, decades of research are ongoing concerning their risks
and impacts.'7 ' In the face of limited knowledge, however, govern-
mental actors must still establish how new technology will be
regulated.
Due to this common scientific and technical uncertainty, and to
a general human proclivity to analogize new experiences to existing
knowledge,'475 reliance on the existing system and rules is often the
most attractive solution at first glance. Using the existing system
is usually the easiest and cheapest answer in the short run: it
471. NAN GOODMAN, SHIFTING THE BLAME: LITERATURE, LAW, AND THE THEORY OF
ACCIDENTS IN NINETEENTH-CENTURY AMERICA 68-69 (1998).
472. ROBERTV. PERCIVAL ET AL., ENVIRONMENTAL REGUIATION: LAW, SCIENCE, AND POLICY
374-538 (3d ed. 2000).
473. GOODMAN, supra note 471, at 68-69.
474. PERCIVAL ET AL., supra note 472, at 374-434.
475. See Mandel, supra note 180.
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requires the least effort to implement and can be developed around
existing and vested interests. Such a solution, however, often
proves unworkable in the long term for the very reasons that it has
in the area of genetically modified products: the new technology
may create concerns and risks so different from previously experi-
enced ones that the rules protecting against earlier risks are
inadequate to handle the new technology. Unfortunately, once
established, legal and regulatory regimes resist change, even as
scientific knowledge and understanding evolve.
The Coordinated Framework was promulgated in 1986, at the
dawn of the biotechnology era. It is not surprising that, in an area
developing as rapidly as biotechnology, a regulatory structure
proposed two decades ago and based on a patchwork of statutes and
regulatory processes created even earlier, would prove fundamen-
tally flawed and unable to adapt to current developments.
Though potentially difficult to implement politically in certain
regards, 76 solutions to many of the regulatory deficiencies identi-
fied in this Article are not difficult to define. Solving them requires
enacting certain additional legislation to close statutory gaps and
promulgating certain new regulations to close regulatory ones. In
addition, to remove the numerous regulatory inconsistencies and
overlaps plaguing this area, and to eliminate the need for agencies
to act outside of their areas of expertise, it is necessary to realign
the regulation of genetically modified products to focus on the
actual risks posed by the products. These risks are now far better
understood than they were when the Coordinated Framework was
promulgated.
Next-generation biotechnological advances are fast-approaching:
the field-testing and production of pharmaceutical-producing and
industrial compound-producing plants are expected to increase
significantly in the coming years and several genetically modified
fish are awaiting approval for commercial use.'77 The risks to
human health and the environment presented by future genetically
476. There are a variety of legal, political, social, psychological, and other practical
phonema that will resist change. Without wading into this vast literature, it is worth noting
one status quo bias of particular relevance here. Regulatory agencies may be expected to be
territorial concerning their areas of oversight, and may try to avoid ceding authority to other
agencies even where it would be more efficient. Mandel, supra note 180, at 44.
477. Field Testing of Pharmaceutical Plants, supra note 23, 68 Fed. Reg. at 11,338;
FUTURE FISH, supra note 25, at 6.
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modified plant varieties, by the production of nonedible and
potentially harmful compounds in crops that have traditionally
been used for food, and by genetically modified fish and other
animals and insects, will include risks of different types than those
posed by transgenic products to date.
The opportunity to optimally reap the potentially spectacular
health, environmental, and economic benefits of these biotechnology
advances will be severely hampered if they are not regulated
properly. The opportunity will be hampered because society will
face inefficient costs and delays and unnecessary risks, and also
because distrust of the regulatory system or future high-profile
problems caused by inadequate regulation could result in a public
backlash against genetically modified products. As we stand at the
portal between first-generation biotechnology and next-generation
biotechnology advances, it is imperative that the statutory and
regulatory structures be properly revised to provide for the effective
and efficient regulation of genetically modified products.
